Top

Varsha Gandhi, Ph.D.

Department of Translational Molecular Pathology, Division of Pathology-Lab Medicine Div

Present Title & Affiliation

Primary Appointment

Professor, Department of Translational Molecular Pathology, Division of Pathology-Lab Medicine Div, The University of Texas MD Anderson Cancer Center, Houston, Texas

Co-Chair, MDA Protect Committee, Department of Institutional Committee under Dr Tereffe and Dr. Kinzel, The University of Texas MD Anderson Cancer Center, Houston, TX

Waun Ki Hong Distinguished Chair in Translational Oncology, Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX

Co-Leader, Chronic Lymphocytic Leukemia (CLL) Moon Shot, Department of Moon Shot Programs at MD Anderson Cancer Center, The University of Texas MD Anderson Cancer Center, Houston, TX

Professor (Joint appointment), Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

Faculty, Department of Graduate School, The University of Texas Graduate School of Biomedical Sciences, Houston, TX

Dual/Joint/Adjunct Appointment

Professor, Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas

Waun Ki Hong Distinguished Chair in Translational Oncology Translational Molecular Pathology, Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas

Professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

Faculty, Department of Graduate School, The University of Texas Graduate School of Biomedical Sciences, Houston, TX

Research Interests

1. Translational research in hematological malignancies

2. Development of single agent and combination therapies for leukemias

3. Transcription inhibitors

4. DNA- and RNA-directed nucleoside analogs, their mechanisms of action and development of resistance

5. Apoptosis modulators as therapeutics (BH3-mimetics, smac-mimetics)

6. Role of microenvironment in hematological malignancies

7. Pim kinase expression and targeting by small molecule inhibitors

Education & Training

Degree-Granting Education

1981	Delhi University, Delhi, IN, Biochemistry, Ph.D
1973	Kanpur University, Kanpur, IN, Botany, M.Sc
1971	Kanpur University, Kanpur, IN, Biology, Chemistry, Physics, B.Sc

Postgraduate Training

1984-1987	Postdoctoral Fellow, The University of Texas MD Anderson Cancer Center, Houston, Texas
1981-1982	Postdoctoral Fellow, Rice University, Houston, Texas
1979-1980	Research Student Assistant, University of Houston, Houston, Texas
1974-1979	Ph.D. Research Fellow, University of Delhi, Delhi

Experience & Service

Faculty Academic Appointments

Faculty Liaison, Department of Office of Postdoctoral Affairs and Development in Education & Training, The University of Texas MD Anderson Cancer Center, Houston, TX, 2018 - 2024

Rebecca Meyer Brown & Joseph Mellinger Brown Chair in Basic Science Research, Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, 2015 - 2020

Ruby E. Rutherford Distinguished Professorship, Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, 2011 - 2015

Ashbel Smith Professorship, Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, 2006 - 2011

Professor, Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, 2002 - 2024

Associate Professor, Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, 1997 - 2002

Assistant Professor, Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, 1991 - 1997

Assistant Pharmacologist, Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, 1989 - 1990

Research Associate, Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, 1987 - 1989

Administrative Appointments/Responsibilities

Co-Chair, MDA Protect Committee, The University of Texas MD Anderson Cancer Center, Houston, TX, 2022 - Present

Co-Leader, Chronic Lymphocytic Leukemia (CLL) Moon Shot, The University of Texas MD Anderson Cancer Center, Houston, TX, 2019 - Present

Faculty Liaison, Department of Office of Postdoctoral Affairs and Development in Education & Training, The University of Texas MD Anderson Cancer Center, Houston, TX, 2018 - Present

Co-Director, Therapeutics and Pharmacology Program (TAP), Department of Graduate School of Biomedical Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX, 2017 - 2018

Department Chair ad interim, Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, 2013 - 2023

Director ad interim, Center for Targeted Therapy, Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, 2013 - 2018

Director, Experimental Therapeutics Academic Program (ETAP), Department of Graduate School of Biomedical Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX, 2009 - 2017

Director of Education and Faculty Development, Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, 2005 - 2013

Deputy Department Chair, Ad interim, Department of Experimental Therapeutics, The University of Texas M.D. Anderson Cancer Center, Houston, TX, 2003 - 2005

Other Professional Positions

Consultant, AbbVie, Chicago, IL, 2022 - Present

Consultant, Atomwise, San Francisco, CA, 2022 - Present

Consultant, Clear Creek Bio, Cambridge, MA, 2020 - 2024

Consultant, Trethera Corporation, Los Angeles, CA, 2018 - 2022

Consultant, BiovelocITA, Italy, 2018 - 2022

External Program Advisory Board (PAB) Member, Roswell Park Cancer Institute, Experimental Therapeutics/Pharmacology and Therapeutics Departmental Retreat, Buffalo, NY, 2017 - Present

AACR Regional Advisory Subcommittee on India Member, AACR International, Philadelphia, PA, 2016 - Present

Committee Member, AACR-American Cancer Society Award for Research Excellence in Cancer Epidemiology and Prevention Awards Committee, Philadelphia, PA, 2015 - 2019

Committee Member, AACR Award for Outstanding Achievement in Cancer Prevention Research Awards Committee, Philadelphia, PA, 2015 - 2019

Committee Member, The University of Texas Kenneth I. Shine, M.D., Academy of Health Science Education, Membership Committee, Houston, TX, 2014 - Present

Consultant, Teva, Israel, 2013 - 2015

Judge, Knudson Best Dissertation Award, Houston, 2011

Consultant for bendamustine, obatoclax and omacetaxine, Cephalon, Frazer, PA, 2010 - 2012

Consultant for post-approval development of clofarabine for adult acute leukemias, Genzyme Oncology, Inc, San Antonio, TX, 2009 - 2010

Consultant for modified nucleoside analogues, NuCana Limited, Oxford, UK, 2008

Consultant and participant for FDA-ODAC meeting for the approval of nelarabine for T-cell pediatric and adult acute leukemias, GlaxoSmithKline Inc, Collegeville, PA, 2005

Consultant for post-approval development of clofarabine for pediatric acute leukemias, Genzyme Oncology Inc, San Antonio, TX, 2005 - 2007

Consultant for clofarabine development in Europe, BioEnvision Limited, Edinburgh, UK, 2005 - 2007

Consultant for combinations of nucleoside analogs with ARQ agents, ArQule Inc, Woburn, MA, 2004 - 2005

Consultant for pharmacodynamic endpoints of BCX-1777, forodesine, BioCryst Pharmaceuticals Inc, Birmingham AL, 2004 - 2008

Consultant and participant for FDA-ODAC meeting for the approval of clofarabine for pediatric acute leukemias, ILEX Oncology Inc, San Antonio, TX, 2004 - 2005

Co-organizer, International Conferences, Translational Cancer Research Conferences in India, Houston, TX, 2003 - Present

Extramural Institutional Committee Activities

Committee Member, T32 Steering Committee, The University of Texas MD Anderson Cancer Center, 2025 - Present

Moon Shots Platform Internal Advisory Board Member, FY24 Moon Shots Operations, The University of Texas MD Anderson Cancer Center, 2023 - Present

Committee Member, Division of Cancer Medicine, Division Head Search Advisory Committee, The University of Texas MD Anderson Cancer Center, 2022 - 2023

Co-Chair, MDA Protect Committee, The University of Texas MD Anderson Cancer Center, 2022 - Present

Member, Regents’ Outstanding Teaching Awards 2021, Nomination Advisory Committee, The University of Texas MD Anderson Cancer Center, 2021

Member, Faculty Advisory Committee for Postdoctoral Fellows, The Office for Training and Mentoring of Scientists, The University of Texas MD Anderson Cancer Center, 2021 - Present

Committee Member, Faculty Academic Affairs: Faculty Track Review Committee (FTRC), The University of Texas MD Anderson Cancer Center, 2021 - 2024

COI Mitigation Reviewer, Division of Cancer Medicine Grand Rounds, The University of Texas MD Anderson Cancer Center, 2021 - 2022

Member, The Morgan Welch Inflammatory Breast Cancer Program Internal Advisory Board, The University of Texas MD Anderson Cancer Center, 2021 - 2022

Member, FY22 Moon Shots Operations: Platform Internal Advisory Board Reviewer, The University of Texas MD Anderson Cancer Center, 2021

Committee Member, Tenure/Tenure Track Review Committee (TTRC), The University of Texas MD Anderson Cancer Center, 2021 - 2024

Committee Member, Search Committee, Program Director Academic Operations - Post Doc Office, The University of Texas MD Anderson Cancer Center, 2021 - 2022

Committee Member, Search Committee, Vice President, Faculty Academic Affairs, The University of Texas MD Anderson Cancer Center, 2020 - 2022

Chair, Promotion and Tenure Committee, The University of Texas MD Anderson Cancer Center, 2020 - 2022

Co-leader, CLL Moon Shot, The University of Texas MD Anderson Cancer Center, 2019 - Present

Vice-Chair, Promotion and Tenure Committee, The University of Texas MD Anderson Cancer Center, 2019 - 2020

Basic Science Faculty Representative, MDA Protect Committee, The University of Texas MD Anderson Cancer Center, 2019 - 2022

Member, Endowed Positions & Award Committee, The University of Texas MD Anderson Cancer Center, 2019 - 2022

Committee Member, GU Medical Oncology Chair Search Advisory Committee, The University of Texas MD Anderson Cancer Center, 2019 - 2021

Member, Visiting Scientist Task Force, The University of Texas MD Anderson Cancer Center, 2018 - 2019

Committee Member, Melanoma Medical Oncology Chair Search Advisory Committee, The University of Texas MD Anderson Cancer Center, 2018 - 2019

Vice President, Therapeutics Discovery, Search Committee, The University of Texas MD Anderson Cancer Center, 2016 - 2017

Co-leader, CLL Moon Shot Flagship Project 1: Drug Development, The University of Texas MD Anderson Cancer Center, 2016 - Present

Member, Associate Professor, Department of Lymphoma & Myeloma Search Committee, The University of Texas MD Anderson Cancer Center, 2015

Member, Division of Cancer Medicine Promotion and Tenure Advisory Committee, The University of Texas MD Anderson Cancer Center, 2015 - 2023

Co-leader, MD Anderson Clinical Innovator Award, The University of Texas MD Anderson Cancer Center, 2014 - 2018

Research Department Chair, 9th Annual Division of Cancer Medicine Faculty Recognition and Awards Program Review Board, The University of Texas MD Anderson Cancer Center, 2014

Co-Host, Offline Session: Non-tenure Research Faculty Embedded in Clinical Departments, The University of Texas MD Anderson Cancer Center, 2014 - 2022

Member, Assistant Professor, Department of Leukemia Search Committee, The University of Texas MD Anderson Cancer Center, 2014

Committee Member, Charles LeMaistre Award Committee, The University of Texas MD Anderson Cancer Center, 2013

Member, Division of Cancer Medicine Hematology/Oncology Fellows Mentorship Discussion, The University of Texas MD Anderson Cancer Center, 2013

Executive Committee Member, Clinical and Translational Sciences, Graduate School of Biomedical Sciences, The University of Texas MD Anderson Cancer Center, 2013 - 2015

Member, MD Anderson Institution Research Executive Committee, The University of Texas MD Anderson Cancer Center, 2013 - 2017

Member, Division of Cancer Medicine Executive Committee, The University of Texas MD Anderson Cancer Center, 2013 - 2023

Member, Assistant Professor, Department of Lymphoma & Myeloma Search Committee, The University of Texas MD Anderson Cancer Center, 2013

Member, MD Anderson Vice Provost for Sciences Committee, The University of Texas MD Anderson Cancer Center, 2013 - 2018

Member, Regents' Outstanding Teaching Awards 2014, Nomination Advisory Committee, The University of Texas MD Anderson Cancer Center, 2013

Chair, Promotion and Tenure Committee, Research Faculty Appointment Panel, The University of Texas MD Anderson Cancer Center, 2012 - 2016

Member, Division of Cancer Medicine Women Faculty & Fellows Initiatives Advisory Council, The University of Texas MD Anderson Cancer Center, 2012 - 2020

Review Panel, 2nd Annual Division of Cancer Medicine Research Awards Program, The University of Texas MD Anderson Cancer Center, 2012

Facilitator, Faculty Round Table, The University of Texas MD Anderson Cancer Center, 2012

Judge, Knudson Best Dissertation Award, The University of Texas MD Anderson Cancer Center, 2011

Focus Group Participation, Speed Mentoring Event, The University of Texas MD Anderson Cancer Center, 2011

GSBS Faculty President, Graduate School of Biomedical Sciences, The University of Texas MD Anderson Cancer Center, 2010 - 2011

Reviewer, MD Anderson Mentorship Awards (Research), The University of Texas MD Anderson Cancer Center, 2010 - 2018

Committee Member, Promotion and Tenure Committee, The University of Texas MD Anderson Cancer Center, 2010 - 2016

Steering Committee Member, Global Academic Program, India Steering Committee, The University of Texas MD Anderson Cancer Center, 2010

Reviewer, MD Anderson Mentor Awards (Clinical), The University of Texas MD Anderson Cancer Center, 2010 - 2018

Therapeutics and Pharmacology Program, Executive Committee Chair, Graduate School of Biomedical Sciences, The University of Texas MD Anderson Cancer Center, 2010 - 2024

GSBS Faculty President-elect, Graduate School of Biomedical Sciences, The University of Texas MD Anderson Cancer Center, 2009 - 2010

Experimental Therapeutics Academic Program, Steering Committee Chair, Graduate School of Biomedical Sciences, The University of Texas MD Anderson Cancer Center, 2009 - 2010

Experimental Therapeutics Academic Program, Founding Director, Graduate School of Biomedical Sciences, The University of Texas MD Anderson Cancer Center, 2009 - 2017

Executive Committee Chair, Graduate School of Biomedical Sciences, The University of Texas MD Anderson Cancer Center, 2009 - 2010

Steering Committee Member, Patient-based Research/Clinical Sciences, Graduate School of Biomedical Sciences, The University of Texas MD Anderson Cancer Center, 2009 - 2015

Program Coordinating Committee Member, Graduate School of Biomedical Sciences, The University of Texas MD Anderson Cancer Center, 2009 - 2017

Coordinator, Graduate School of Biomedical Sciences Course, Principles of Therapeutics, The University of Texas MD Anderson Cancer Center, 2008 - 2009

Chair, Postdoctoral Advisory Committee, The University of Texas MD Anderson Cancer Center, 2007 - 2008

Chair, Experimental Therapeutics Seminar Series, The University of Texas MD Anderson Cancer Center, 2007 - 2010

Committee Member, Faculty Mentoring Advisory Committee, The University of Texas MD Anderson Cancer Center, 2007 - 2022

Chair Elect, Postdoctoral Advisory Committee, The University of Texas MD Anderson Cancer Center, 2006 - 2007

Member, Postdoctoral Advisory Committee, The University of Texas MD Anderson Cancer Center, 2006 - 2008

Organizing Committee Member, Experimental Therapeutics Website, The University of Texas MD Anderson Cancer Center, 2005 - 2010

Organizing Committee Member, Experimental Therapeutics Newsletter, The University of Texas MD Anderson Cancer Center, 2005 - 2010

Organizing Committee Member, Division of Cancer Medicine Grand Rounds, The University of Texas MD Anderson Cancer Center, 2005 - Present

Member, Odyssey Postdoctoral Program Review Committee, The University of Texas MD Anderson Cancer Center, 2005 - 2008

Curriculum Committee Member, Graduate School of Biomedical Sciences, The University of Texas MD Anderson Cancer Center, 2005 - 2008

Reviewer, Seed Grants, Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, 2003

Chair, Conflict Management Advisory Committee, The University of Texas MD Anderson Cancer Center, 2003 - 2004

Member, Conflict of Interest Committee, The University of Texas MD Anderson Cancer Center, 2003 - 2007

Coordinator GSBS Course, Mechanisms in Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, 2003 - 2009

Focus Group Participation, Organization of Research, The University of Texas MD Anderson Cancer Center, 2001

Member, Conflict Management Advisory Committee, The University of Texas MD Anderson Cancer Center, 2001 - 2005

Chair, Organizing Committee, Experimental Therapeutics Seminar Series, The University of Texas MD Anderson Cancer Center, 2001 - 2007

Member, Executive Committee of Faculty Senate, The University of Texas MD Anderson Cancer Center, 2000 - 2005

Department Representative, Appeals Panel, Faculty Peer & Grievance Review, The University of Texas MD Anderson Cancer Center, 2000 - 2004

Member, Research Council Subcommittee, Research Laboratory Space Committee (Dr. Klein - Chair), The University of Texas MD Anderson Cancer Center, 2000 - 2003

Chair, Minority Faculty and Administrative Committee, The University of Texas MD Anderson Cancer Center, 1999 - 2000

Member, Research Council Subcommittee, Research Laboratory Space Committee (Dr. DiGiovanni -Chair), The University of Texas MD Anderson Cancer Center, 1999

Member, Subcommittee, Faculty Peer and Grievance Review Committee, The University of Texas MD Anderson Cancer Center, 1999

Judge, Trainee Recognition Day, M.D. Anderson Associates, The University of Texas MD Anderson Cancer Center, 1999

Member, Graduate School of Biomedical Sciences Academic Standards Committee, The University of Texas MD Anderson Cancer Center, 1999 - 2002

Member, Study Section Review Committee, Basic Research Projects, Institutional Research Grants Program, The University of Texas MD Anderson Cancer Center, 1999 - 2002

Focus Group Participation, Institutional Diversity Faculty Focus Group, The University of Texas MD Anderson Cancer Center, 1998

Chair Elect, Minority Faculty and Administrative Committee, The University of Texas MD Anderson Cancer Center, 1998 - 1999

Department Representative, Faculty Senate, The University of Texas MD Anderson Cancer Center, 1998 - 2005

Focus Group Participation, Faculty Compensation Project, The University of Texas MD Anderson Cancer Center, 1998

Member, Animal Care & Use Committee, The University of Texas MD Anderson Cancer Center, 1993 - 1995

Member, Minority Faculty and Administrative Committee, The University of Texas MD Anderson Cancer Center, 1993 - 2000

Editorial Activities

Editorial Board Member, Blood Neoplasia, 2024 - Present

Founding Editor-in-Chief, Lymphatics, 2022 - Present

Section Head of the Oncologic Drugs Section, Faculty of 1000 Medicine (www.f1000.com), 2019 - Present

Editorial Board Member, Leukemia, 2015 - 2018

Guest Associate Editor, Leukemia, 2014 - 2018

Section Editor, Emerging Drug Profile, Leukemia and Lymphoma, 2013 - Present

Associate Editor, Frontiers in Oncology-Hematology, 2011 - 2025

Founding Editor, American Journal of Blood Research, 2011 - Present

Associate Editor, Leukemia and Lymphoma, 2008 - Present

Editorial Board Member, Advances in Hematology, 2008 - 2018

Editorial Board Faculty Member of Lymphomas and Myelomas Section, Faculty of 1000 Medicine (www.f1000.com), 2008 - Present

Editorial Board Member, Blood, 2007 - 2011

Editorial Board Member, Leukemia and Lymphoma, 2006 - 2008

Editorial Board Member, Clinical Cancer Research, 2003 - Present

Honors & Awards

2024	Keynote Presenter, ITERT STEM Training and Education Program (STEP), The University of Texas MD Anderson Cancer Center
2024	Shri R.J. Kinarivala Research Award from GCRI and GCS, Gujarat Cancer Research Institute and Gujarat Cancer Society, Ahmedabad, Gujarat State, India
2024	Award and Plenary Speaker, Annual Cancer Research Day, Indiana University Simon Cancer Center
2023	Chronic Lymphocytic Leukemia (CLL) Moon Shot, Co-Leader for Moon Shot Project 1 and Project 2
2021	MD Anderson Distinguished Educator 2021-2023, The University of Texas MD Anderson Cancer Center
2020	MD Anderson Distinguished Educator, The University of Texas MD Anderson Cancer Center
2020	Waun Ki Hong Distinguished Chair in Translational Oncology, The University of Texas MD Anderson Cancer Center
2019	MD Anderson Distinguished Educator, The University of Texas MD Anderson Cancer Center
2018	Dr. John S. McMurray Lifetime TAP Achievement Award 2018-2019, The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences
2015	The William Randolph Hearst Foundations Faculty Achievement Award in Education, The University of Texas MD Anderson Cancer Center
2015	Chronic Lymphocytic Leukemia (CLL) Moon Shot, Co-Leader for Project 1 2015-2023
2015	Rebecca Meyer Brown & Joseph Mellinger Brown Chair in Basic Science Research 2015-2020, The University of Texas MD Anderson Cancer Center
2014	Fellow-AAAS, American Association for the Advancement of Science
2013	Outstanding Service and Dedication as GSBS Program Director, Graduate School of Biomedical Sciences
2013	Exceptional Leadership & Support as a Mentor, MD Anderson Alumni & Faculty Association
2013	Member, The University of Texas Kenneth I. Shine, M.D., Academy of Health Science Education
2013	Outstanding Women Scientist Award, American Association of Indian Scientists in Cancer Research
2012	Outstanding Service and Dedication as ETAP Program Director, Graduate School of Biomedical Sciences
2012	Appointment with highest commendation, Graduate School of Biomedical Sciences
2012	Executive Development Seminar for Interim and Aspiring Leaders, Association of American Medical Colleges, Washington DC
2012	The University of Texas System Regents Outstanding Teaching Award - Health, The University of Texas System, Austin, TX
2011	Distinguished Research Faculty Mentor Award, The University of Texas MD Anderson Cancer Center
2011	Ruby E. Rutherford Distinguished Professorship 2011-2015, The University of Texas MD Anderson Cancer Center
2009	Faculty Leadership Academy, MD Anderson Cancer Center
2009	Gerald P. Bodey Award for Excellence in Education 2009-2010, Division of Cancer Medicine Faculty Recognition & Award Program
2007	Potu N. Rao Award for Excellence in Basic Science, Division of Cancer Medicine Faculty Recognition & Award Program
2007	Appointment with commendation, Graduate School of Biomedical Sciences
2006	Ashbel Smith Professorship 2006-2011, The University of Texas MD Anderson Cancer Center
2005	Robert M. Chamberlain Distinguished Mentor Award, Postdoctoral Association Steering Committee, The University of Texas MD Anderson Cancer Center
2003	Aventis Drug Development Award 2003-2004, The University of Texas MD Anderson Cancer Center
1999	E.N. Cobb Faculty Scholar Award 1999-2002, The University of Texas MD Anderson Cancer Center
1998	NIH-RAID-I Award 1998-2000, National Cancer Institute, Bethesda, MD
1976	Senior Research Scholarship 1976-1977, University Grants Commission, University of Delhi, India
1975	Junior Research Scholarship, University Grants Commission, University of Delhi, India
1974	Junior Research Scholarship 1974-1976, University Grants Commission, University of Delhi, India
1973	M.Sc. Gold Medal Winner, Kanpur University, India

Professional Memberships

Purine and Pyrimidine Society

2021 - Present

European Hematology Association

2019 - Present

American Society of Pharmacology and Experimental Therapeutics

2011 - Present

Indo American Cancer Association

2005 - Present

Women in Cancer Research

2000 - Present

International Society of Nucleosides, Nucleotides & Nucleic Acids

2000 - Present

American Association of Indian Scientists in Cancer Research

1998 - Present

International Association of Therapeutic Drug Monitoring

1995 - Present

American Association for the Advancement of Science

1992 - Present

American Society of Hematology

1992 - Present

American Society of Clinical Oncology

1991 - Present

American Association for Cancer Research

1988 - Present

Selected Presentations & Talks

Local Presentations

2025. Translational Research to Transformative Medicine. Invited. DPLM - Grand Rounds. Houston, Texas, US.
2024. STEP Graduation Speech. Invited. ITERT Summer Undergraduate Training Program 2024. Houston, Texas, US.
2024. Science-driven dosing and combination of ibrutinib for CLL. Invited. Leukemia in 2024: State of the Art. Houston, TX, US.
2023. Translational Research to Transformative Therapy in CLL. Invited. The University of Texas Health Science Center. Houston, TX, US.
2023. Science-Driven Therapy of Chronic Lymphocytic Leukemia. Invited. ENJOY SCIENCE Webinar Series. Houston, TX, US.
2023. Curative Targeted Therapy of CLL. Invited. MoonShots Scientific Seminar. Houston, TX, US.
2023. Crafting Combinations to Combat Cancer. Invited. Department of Cancer Biology Chalk Talk and Social Hour. Houston, TX, US.
2022. Effective Management of Multiple Projects. Invited. Navigating Academic Career Series Course for Postdocs. Houston, TX, US.
2022. ITERT Core - Serving an Institutional Unmet Need in Education & Training. Invited. ITERT Core Service Launch Event. Houston, TX, US.
2022. Breakthrough Houston Panel Discussion. Invited. Breakthrough Houston Panel Discussion. Zoom, US.
2022. Promotion & Tenure Session for Tenure/Tenure Track Mid-Career Faculty. Invited. Promotion & Tenure Session for Tenure/Tenure Track Mid-Career Faculty. Virtual Meeting, US.
2022. Promotion & Tenure Session for Tenure/Tenure Track Junior Faculty. Invited. Virtual Meeting, US.
2022. Chair Memo Panel Discussion. Invited. Community of Chairs Meeting. Zoom, US.
2022. Authorship Conflicts and Panel Discussion. Invited. Authorship Conflicts and Panel Discussion. Virtual Meeting, US.
2022. The Impact of Organizational Mentorship Culture. Invited. The Impact of Organizational Mentorship Culture. Virtual Meeting, US.
2022. Panel Discussion: Defining Core Elements of Successful Mentorship Practices in Science. Invited. Panel Discussion: Defining Core Elements of Successful Mentorship Practices in Science. Virtual Meeting, US.
2022. Navigating Academic Careers. Invited. Navigating Academic Careers. Virtual Meeting, US.
2021. Successful Scientists: Stories behind the CV. Invited. Successful Scientists: Stories behind the CV. Virtual Meeting, US.
2021. Mid-Career Faculty: Tenure and Tenure Track Session with the PTC. Invited. Mid-Career Faculty: Tenure and Tenure Track Session with the PTC. Virtual Meeting, US.
2020. Promotion & Tenure Session: Tenure Track Junior Faculty. Invited. Promotion & Tenure Session: Tenure Track Junior Faculty. Virtual Meeting, US.
2018. Cancer Therapeutics. Invited. CPRIT CURE Summer Program, Summer Experience Lecture Series. Houston, TX, US.
2018. Networking for a Successful Career in Academic Medicine. Invited. Networking for a Successful Career in Academic Medicine. Houston, TX, US.
2017. Cancer Therapeutics. Invited. CPRIT CURE Summer Program, Summer Experience Lecture Series. Houston, TX, US.
2017. Optimal dosing of Ibrutinib in CLL: Reducing toxicity and cost while maintaining effectiveness. Invited. Advances in Oncology Institutional Grand Rounds. Houston, TX, US.
2017. Lower dose ibrutinib for chronic lymphocytic leukemia. Invited. Houston, TX, US.
2017. Developing your Leadership Potential: Pathways to Leadership for Women Assistant and Associate Professors, Workshop Panelist. Invited. Developing your Leadership Potential: Pathways to Leadership for Women Assistant and Associate Professors, Workshop Panelist. Houston, TX, US.
2016. Playing the Game: National and International Networks. Invited. Playing the Game: National and International Networks. Houston, TX, US.
2016. Mechanism of resistance and rationale for combination. Invited. Advances in Oncology Institutional Grand Rounds. Houston, TX, US.
2016. Targeting PI3K in Chronic Lymphocytic Leukemia. Invited. Advances in Oncology Institutional Grand Rounds, Session Chair. Houston, TX, US.
2016. Cancer Treatment: How to Make Informed Choices about Standard Care and Clinical Trials. Invited. Cancer Treatment: How to Make Informed Choices about Standard Care and Clinical Trials. Houston, TX, US.
2014. Developing novel therapeutic. Invited. Texas 4000 Team Visit. Houston, TX, US.
2014. Mechanism-based combinations of ibrutinib in CLL. Invited. Advances in Oncology Institutional Grand Rounds. Houston, TX, US.
2013. Targeting Bcl-2 Family Survival Proteins - A New Concept in Chemotherapy. Invited. Division of Cancer Medicine - Grand Rounds. Houston, TX, US.
2013. Stepping Stones for Success. Invited. Stepping Stones for Success. Houston, TX, US.
2013. Targeting Bcl-2 Family Survival Proteins: A New Concept in Chemotherapy. Invited. Department of Experimental Therapeutics Seminar Series. Houston, TX, US.
2013. Gossypol: From Natural Product to Novel Strategy. Invited. Integrative Medicine Program Lecture Series. Houston, TX, US.
2010. Targeting Met Kinase in Multiple Myeloma. Invited. Department of Experimental Therapeutics Research Seminars. Houston, TX, US.
2010. Targeting Bcl-2 Survival Proteins: A New Concept in Chemotherapy. Invited. Division of Cancer Medicine Grand Rounds. Houston, TX, US.
2010. Individual Career Developmental Plan. Invited. Individual Career Developmental Plan. Houston, TX, US.
2009. CLL: A model to test Bcl-2 antagonists. Invited. Oncology Grand Rounds. Houston, TX, US.
2008. 8-Chloro-Adenosine: Preclinical Review and Clinical Preview. Invited. Department of Leukemia, Hematology Grand Round. Houston, TX, US.
2006. Forodesine. Invited. Hematology Grand Rounds. Houston, TX, US.
2006. Targeting T-Cell Lymphomas. Invited. Department of Lymphoma Grand Rounds. Houston, TX, US.
2005. Transcription Inhibition: C-Met as a Target. Invited. Division of Cancer Medicine Grand Rounds. Houston, TX, US.
2004. Interfering with Oncogene Addiction: A Concept for Therapeutics. Invited. Houston, TX, US.
2004. Interfering with Oncogene Addiction: A Concept for Therapeutics. Invited. Division of Cancer Medicine Grand Rounds. Houston, TX, US.
2003. Clofarabine in adult acute leukemias: Cellular pharmacokinetics and clinical response. Invited. Pediatric Leukemia/Lymphoma Team Meeting. Houston, TX, US.
2003. Adenosine analogs: Hypothesis to Clinic. Invited. Houston, TX, US.
2002. Pharmacology and its role in clinical trial design. Invited. Pharmacology and its role in clinical trial design. Houston, TX, US.
2002. Adenosine analog that affects the mitochondrial machinery. Invited. Houston, TX, US.
2002. Halogenated ATP affects the mitochondrial machinery. Invited. Houston, TX, US.
2001. 8-Cl-cAMP for multiple myeloma. Invited. Houston, TX, US.
2001. Adenosine analog that affects the mitochondrial machinery. Invited. Houston, TX, US.
2001. New therapies for multiple myeloma. Invited. Multiple Myeloma Annual Retreat. Houston, TX, US.
2001. Strategies for Combination Chemotherapy in Cancer. Invited. Houston, TX, US.
2001. Strategies for Combination Chemotherapy in Cancer. Invited. Houston, TX, US.
2000. Mechanism based combination chemotherapy. Invited. Seminar for Medical Students and Fellows. Houston, TX, US.
1999. Arabinosylguanine. Invited. Clinical/Basic Research Pediatric Rounds. Houston, TX, US.
1998. Arabinosylguanine: A new kid on the block. Invited. Pediatric Research Conference. Houston, TX, US.
1998. Arabinosylguanine: Past, Present, and Future. Invited. Department of Clinical Investigation Seminar Series. Houston, TX, US.
1997. Arabinosylguanine and New Strategies for T-Cell Diseases. Invited. Clinical Oncology Grand Rounds. Houston, TX, US.
1997. Arabinosylguanine: A remarkable agent for T-ALL. Invited. Section of Bioimmunotherapy Seminar Series. Houston, TX, US.
1997. Arabinosylguanine: Pharmacokinetics, pharmacodynamics, and correlates with clinical response. Invited. Division of Laboratory Medicine Seminar Series. Houston, TX, US.
1996. 506U (ara-G): Metabolism, mechanisms of action, and clinical pharmacology. Invited. Hematology/Oncology Section Research Meeting. Houston, TX, US.
1996. 506U (ara-G): An effective agent for the treatment of T-cell malignancies. Invited. Department of Hematology Clinical Research Conference. Houston, TX, US.
1995. Modulation of ara-C: Pharmacological, clinical, and molecular interactions. Invited. Pediatric Research Conference. Houston, TX, US.
1993. Fludarabine modulation of ara-C: Bench to bedside and back to bench. Invited. Section of Immunology and Drug Delivery Seminar Series. Houston, TX, US.
1993. Fludarabine & ara-C: Mechanistically derived rationale for combination. Invited. Laboratory Medicine Seminar Series. Houston, TX, US.
1992. Pharmacologic rationale for combination therapy. Invited. Department of Pediatrics: Section Update Conference. Houston, TX, US.
1991. Fludarabine modulation of ara-C: Bench to bedside. Invited. Department of Hematology Seminar Series. Houston, TX, US.

National Presentations

2024. CLL therapy: Webinar. Invited. Virtual Meeting, US.
2024. Translational Research to Transformative Therapy in CLL. Invited. Special Seminar, Karmanos Cancer Center. Detroit, MI, US.
2024. Translational Research to Transformative Medicine. Invited. Cancer Reasearch Day. Indianapolis, Indiana, US.
2024. Pirtobrutinib. Invited. CLL-GRF Alliance Meeting. Houston, TX, US.
2023. Resistance to non-covalent BTKi in CLL: Focus on Pirtobrutinib. Conference. International Workshop on Chronic Lymphocytic Leukemia. Boston, MA, US.
2023. Dosing of Ibrutinib for CLL. Conference. 3rd Optimal Cancer Care Alliance Meeting. Virtual Meeting, US.
2023. New action of ibrutinib. Conference. CLL Global Research Foundation Annual Meeting. Houston, TX, US.
2022. Work Life Integration Strategies, Panelist. Conference. Work Life Integration Strategies, Panelist. Virtual Meeting, US.
2022. Biology of CLL and basis of use of BTKi and Bcl2i. Conference. CLL MasterClass Educational Program. New Orleans, LA, US.
2022. Leveraging Bruton Tyrosine Kinase Inhibitors for the Treatment of CLL/SLL: Seeking Improved Outcomes. Conference. JADPRO Live. Aurora, CO, US.
2022. Role of Clinical Pharmacodynamics to Select Optimal Dose of Targeted Agents: Ibrutinib as a Paradigm. Conference. Utilizing Quantitative Clinical Pharmacology and Interventional Pharmacoeconomics to More Efficiently Optimize Dose Regimens. Bethesda, MD, US.
2022. Translational Research to Transformative Therapy in CLL. Invited. Translational Research to Transformative Therapy in CLL. Buffalo, NY, US.
2022. Science-driven Dosing of Ibrutinib in Chronic Lymphocytic Leukemia. Conference. 2022 ACVIM Forum. Austin, TX, US.
2021. Mechanism-based combination to cure CLL. Invited. Mechanism-based combination to cure CLL. Virtual Meeting, US.
2021. Global Scholar-In-Training Award Flash Presentation, Panelist. Conference. Global Scholar-In-Training Award Flash Presentation, Panelist. Virtual Meeting, US.
2020. Global Scholar-In-Training Professional Development Session, Panelist. Conference. Global Scholar-In-Training Professional Development Session, Panelist. Virtual Meeting, US.
2019. Mechanism-based combination to cure CLL. Invited. Mechanism-based combination to cure CLL. Buffalo, NY, US.
2019. Mcl-1 inhibitors in CLL. Conference. Expert Forum on Chronic Lymphocytic Leukemia. Dallas, TX, US.
2018. Changes in transcriptomics during combination therapy in CLL. Conference. Changes in transcriptomics during combination therapy in CLL. Dallas, TX, US.
2018. Targeting Bruton’s tyrosine kinase in CLL. Invited. Targeting Bruton’s tyrosine kinase in CLL. New York, NY, US.
2017. Translational Research in Heme Malignancies. Invited. Translational Research in Heme Malignancies. Buffalo, NY, US.
2017. Optimizing BTK therapy for CLL: Lessons learned from laboratory models. Conference. Optimizing BTK therapy for CLL: Lessons learned from laboratory models. Dallas, TX, US.
2017. Attacking antiapoptosis in CLL. Conference. Attacking antiapoptosis in CLL. Dallas, TX, US.
2017. Careers in Academia. Conference. AACR Women in Cancer Research. Washington, DC, US.
2016. Targeting B-cell Receptor Pathway in B-cell Malignancies. Invited. Targeting B-cell Receptor Pathway in B-cell Malignancies. Silver Spring, MD, US.
2016. Careers in Academia. Conference. AACR Women in Cancer Research. New Orleans, LA, US.
2015. Vulnerability of LKBI deficient NSCLC to adenosine analogs. Conference. 16th International Symposium on Purine and Pyrimidine Metabolism in Man. New York, NY, US.
2015. Translational Research in Heme Malignancies. Invited. Translational Research in Heme Malignancies. Tucson, AZ, US.
2014. 8-Chloro-Adenosine as a Promising Molecule for RAS and LKB1 Mutant NSCLC. Conference. Nucleic Acid Research and Discovery Conference. San Diego, CA, US.
2014. Targeting Met Receptor Tyrosine Kinase in High-risk Myeloma Patients. Conference. Translational Research Program Progress Review Meeting. Washington, DC, US.
2014. Careers in Academia. Conference. AACR Women in Cancer Research. San Diego, CA, US.
2013. Targeting Bcl-2 Survival Proteins: A New Concept in Chemotherapy. Invited. Targeting Bcl-2 Survival Proteins: A New Concept in Chemotherapy. New York, NY, US.
2013. 8-Cl-Adenosine as Anticancer Agent. Conference. 8-Cl-Adenosine as Anticancer Agent. Newport, RI, US.
2012. Pim Kinase Inhibition. Conference. Research Symposium. New York, NY, US.
2011. ASH Trainee Career Development Lunch - PhD Careers. Conference. ASH Trainee Career Development Lunch - PhD Careers. San Diego, CA, US.
2011. Targeting Met receptor tyrosine kinase in myeloma. Invited. Targeting Met receptor tyrosine kinase in myeloma. New York, NY, US.
2011. Nucleoside Analogues as Anticancer and Antiviral Agents. Conference. Nucleoside Analogues as Anticancer and Antiviral Agents. Newport, RI, US.
2011. Targeting Met receptor tyrosine kinase in myeloma. Invited. Targeting Met receptor tyrosine kinase in myeloma. West Lafayette, IN, US.
2010. Novel Bcl-2 Antagonists. Conference. CLL Think Tank Meeting. Orlando, FL, US.
2010. Targeting Bcl-2 Survival Proteins: A New Concept in Chemotherapy. Invited. Stanley S. Scott Cancer Center Seminars. New Orleans, LA, US.
2010. Targeting Bcl-2 Survival Proteins: A New Concept in Chemotherapy. Invited. Rochester, MN, US.
2010. Hematological malignancies: MDACC-SBMRI Workshop - Drug Discovery and Translational Opportunities. Invited. Hematological malignancies: MDACC-SBMRI Workshop - Drug Discovery and Translational Opportunities. La Jolla, CA, US.
2009. Targeting Met Receptor Tyrosine Kinase in Multiple Myeloma. Conference. Research Symposium. Springfield, IL, US.
2009. Introduction, Kenneth B. McCredie Memorial Lecture. Conference. Research Symposium, 24th International Association for Comparative Research on Leukemia and Related Diseases (IACRLRD). Columbus, OH, US.
2009. CLL: A model to test Bcl-2 antagonists. Invited. Leukemogenesis Seminar Series. Manhasset, NY, US.
2009. Chair. Conference. Gordon Research Conference on Nucleosides, Nucleotides, and Oligonucleotides. Newport, RI, US.
2009. Targeting anti-apoptotic proteins. Invited. Indianapolis, IN, US.
2008. BLyS-Gelonin: A Targeted Therapeutics for CLL. Conference. Translational Research Program Progress Review Meeting. New York, NY, US.
2008. Chemistry of nucleoside analogs. Conference. Annual Symposium on Lymphoma and Myeloma 2008. New York, NY, US.
2008. New Agents in T-cell Disease. Conference. Leukemia 2008. Houston, TX, US.
2008. Role of Nucleoside Analogs in PTCL. Conference. Washington, DC, US.
2008. Role of Pharmacokinetics and Pharmacodynamics in Cancer Therapy. Invited. Department of Pharmacology, College of Medicine. Columbus, OH, US.
2008. 11th Annual Grant Writing Workshop. Conference. American Association for Cancer Research, Educational Session, Associate Member Grant Writing Workshop, Participant, Mock Study Section. San Diego, CA, US.
2008. 11th Annual Grant Writing Workshop. Conference. American Association for Cancer Research, Educational Session, Associate Member Grant Writing Workshop, Discussion Leader. San Diego, CA, US.
2008. Role of Exonucleases of replicative DNA Polymerases in Gemcitabine Medicated Damage Response and Cytotoxicity. Invited. Role of Exonucleases of replicative DNA Polymerases in Gemcitabine Medicated Damage Response and Cytotoxicity. Round Top, TX, US.
2007. 10th Annual Grant Writing Workshop. Conference. AACR Educational Session, Associate Member Grant Writing Workshop, Discussion Leader. Anaheim, CA, US.
2007. Mechanism Based Chemotherapy. Invited. Department of Chemistry and Biology Seminar. El Paso, TX, US.
2006. Nucleoside Analogs in Leukemia. Conference. 48th Annual Meeting of the American Society of Hematology, Meet The Expert Session. Orlando, FL, US.
2006. Forodesine, Preclinical studies. Conference. BioCryst Investigators Meeting. Orlando, FL, US.
2006. DNA Independent Strategy to Target CLL. Conference. The Leukemia and Lymphoma Society, Translational Research Award Symposium. San Diego, CA, US.
2006. Targeting cMet Receptor Tyrosine Kinase. Invited. Department of Pharmacology. Piscataway, NJ, US.
2006. 9th Annual Grant Writing Workshop, Educational Session, Participant, Mock Study Section. Conference. American Association for Cancer Research Meeting. Washington, DC, US.
2006. Targeting T-Cell Leukemias. Invited. Comprehensive Cancer Center Grand Rounds. Columbus, OH, US.
2005. Clofarabine - Drug for Acute Leukemias. Conference. Eastern Cooperative Oncology Group (ECOG) Meeting. Tampa, FL, US.
2005. Targeting T-cell Malignancies: Old Concept. Invited. New Therapeutics, Departments of Biochemistry and Pharmacology. New York, NY, US.
2005. Targeting c-Met in Multiple Myeloma. Conference. Third Annual Conference: Therapeutic Advances in the Treatment of Hematological Malignancies. Santa Monica, CA, US.
2005. Nucleoside, Nucleotide, and Oligonucleotides, Small Molecules and Targets, Chair of Session. Conference. Newport, RI, US.
2005. Novel Therapeutic Targets from A to Z, Member, Co-chair for Scientific Session. Conference. 96th Annual Meeting of American Association for Cancer Research. Anaheim, CA, US.
2005. Experimental Therapeutics Small Molecules, Member, Organizing committee for Scientific Session. Conference. 96th Annual Meeting of American Association for Cancer Research. Anaheim, CA, US.
2005. Organizer and Chair for Educational Session, Transcription as a target for cancer therapeutics. Conference. 96th Annual Meeting of American Association for Cancer Research. Anaheim, CA, US.
2005. 8th Annual Grant Writing Workshop, Educational Session, Participant, Mock Study Section. Conference. 96th Annual Meeting of American Association for Cancer Research,. Anaheim, CA, US.
2005. 8th Annual Grant Writing Workshop. Conference. 96th Annual Meeting of American Association for Cancer Research, Educational Session, Discussion Leader. Anaheim, CA, US.
2005. Inhibition of oncogene expression, Presenter in the Educational Session. Conference. 96th Annual Meeting of American Association for Cancer Research. Anaheim, CA, US.
2004. Cellular pharmacology in the evaluation of emerging new drugs for leukemias. Conference. ASH, Corporate Symposia. San Diego, CA, US.
2004. Cellular pharmacology in the evaluation of emerging new drugs for leukemias. Conference. Leukemia 2004: Towards the Cure. Houston, TX, US.
2004. DNA versus RNA directed nucleoside analogs. Conference. Second Annual Conference: Targeted Therapies for the Treatment of Hematological Malignancies. Kauai, HI, US.
2004. Targeting Transcription and Bioenergy. Invited. Department of Biochemistry and Molecular Genetics. Chicago, US.
2004. Clofarabine: Pharmacokinetic and pharmacodynamics. Conference. NCI and CLL Research Consortium. Bethesda, MD, US.
2004. Targeting Bioenergy and Transcription. Invited. Department of Molecular Pharmacology. Philadelphia, PA, US.
2003. Clofarabine in acute leukemias: Relationship between pharmacokinetics, pharmacodynamics, and clinical response. Conference. ProQuest Investments Scientific Meeting. Princeton, NJ, US.
2003. Deoxyadenosine and its analogs: From deoxycoformycin to clofarabine. Conference. First Annual Conference: Targeted Therapies for the Treatment of Hematological Malignancies. Kona, HI, US.
2003. ATP Analogs: Cellular bioenergetics and transcription. Conference. Gordon Research Conference, Purines, Pyrimidines & Related Substances. Newport, RI, US.
2003. Pharmacodynamics of clofarabine. Conference. Annual European Hematological Society (EHA) Clofarabine Investigators Meeting. Lyon, FR.
2002. Pharmacokinetics and pharmacodynamics of clofarabine. Conference. Bioenvision European Investigators Meeting. Philadelphia, PA, US.
2002. Development of clofarabine. Conference. Golfers Against Cancer - Annual Meeting. Houston, TX, US.
2002. Clofarabine in acute leukemias. Conference. Leukemia 2002: Towards the Cure. Miami, FL, US.
2001. Nelarabine: Pharmacokinetics and clinical responses. Conference. Birmingham, Alabama, US.
2001. Clofarabine: cellular pharmacology and combinations strategies. Invited. Annual meeting of the CLL Research Consortium. La Jolla, CA, US.
2001. Strategies for Combination Chemotherapy in Cancer. Conference. 4th Foundations of Clinical Cancer Research Symposium: Triumphs and Challenges in Oncology. Houston, TX, US.
2000. Gemcitabine: Pharmacokinetics and mechanism of actions. Conference. VIII Annual Radiation Workshop at Round Top: Biology-Based Combined Modality Radiotherapy. Round Top, TX, US.
2000. Biochemical modulation strategy for nucleoside analog resistance. Conference. Acute Myelogenous Leukemia, Session: Drug Resistance. Rockville, MD, US.
2000. Cell cycle dysregulation strategy for nucleoside analog resistance. Conference. Acute Myelogenous Leukemia, Session: Drug Resistance. Rockville, MD, US.
1999. Novel inhibitors of DNA replication. Conference. 41st Annual Meeting of American Society of Hematology, Educational Session, Molecular Pharmacology of Novel Anti-Cancer Drugs. New Orleans, US.
1999. GW506U78, alternate day schedule: Cellular pharmacology investigations. Invited. Investigators Meeting on compound 506U78. Bethesda, MD, US.
1999. Cellular pharmacology investigations during phase I (PGAA1001 and PGAA1005) studies. Invited. Investigators Meeting on compound 506U78. Bethesda, MD, US.
1999. New antimetabolites in clinic: Arabinosylguanine. Conference. Gordon Research Conference, Purines, Pyrimidines & Related Substances. Newport, RI, US.
1999. Arabinosylguanine: A new clinically active nucleoside analog. Invited. Lurie Comprehensive Cancer Center. Chicago, IL, US.
1999. Arabinosylguanine: A new clinically active nucleoside analog. Invited. Chicago, IL, US.
1999. Metabolic and mechanistic studies on 8-chloro-adenosine- A nucleoside analog. Invited. NCI RAID Investigators Meeting on 8-chloro-adenosine. Frederick, MD, US.
1998. A challenging case of hematologic malignancy. Conference. Hematologic Malignancies… The Next Questions. Chicago, IL, US.
1998. GW506U78 (a prodrug of arabinosylguanine): cellular pharmacokinetics and clinical responses. Conference. Hematologic Malignancies...The Next Questions. Chicago, US.
1998. GW506U78, a prodrug of arabinosylguanine: pharmacokinetics and clinical responses. Invited. Department of Clinical Pharmacology. Triangle Park, NC, US.
1998. Growth factors and nucleoside analogs for treatment of leukemia. Conference. VI Annual Radiation Workshop at Round Top. Round Top, TX, US.
1997. Pharmacokinetics of arabinosylguanine. Conference. Purines, Pyrimidines & Related Substances. New London, New Hampshire, US.
1997. Arabinosylguanine (ara-G, Compound GW506U): A highly-effective compound in T-cell acute lymphoblastic leukemia. Invited. Department of Hematology and Oncology. Memphis, TN, US.
1996. Rationale and pharmacology of combination of cladribine and ara-C. Invited. Department of Hematology/Oncology. Memphis, TN, US.
1996. Cellular metabolism and action on DNA synthesis. Invited. Compound 506U Investigators' Meeting. Durham, NC, US.
1995. Nucleoside analogs and monitoring in cancer: Historical perspectives and analogy with antiretrovirals. Conference. Meeting on Zidovudine Phosphorylation in Patients: Methods and Clinical Relevance. Memphis, TN, US.
1994. Pharmacological, clinical, and molecular rationale for combining fludarabine and ara-C for therapy of AML. Invited. Chicago, IL, US.
1994. Pharmacologically directed design of AML therapy: ara-C as a paradigm. Invited. Department of Pathology and Lab Medicine. Cincinnati, OH, US.
1993. Fludarabine and ara-C combination: Biochemical and molecular rationale for clinical success. Invited. Division of Hematology/Oncology Seminar Series. Charleston, SC, US.
1993. Fludarabine modulates ara-C metabolism. Conference. Purines, Pyrimidines & Related Substances. Newport, RI, US.
1993. Does fludarabine make ara-C a better drug?. Conference. Leukemia the next questions…. Houston, TX, US.
1993. Mode of action of fludarabine. Conference. Representatives' Meeting. Scottsdale, AZ, US.
1992. Biochemical modulation of ara-C by fludarabine. Conference. NCI Phase I meeting on the Biochemical Modulation of Antimetabolites. Bethesda, MD, US.
1992. Lymphoma, the next questions... Conference. Rationale for combinations. Orlando, FL, US.

International Presentations

2025. Proteomics Changes During Ibrutinib Therapy. In Session. Genomics, Epigenetics, and Proteomics in CLL. Conference. International Workshop on Chronic Lymphocytic Leukemia. Krakow, PL.
2024. Transcriptomic Clustering of CLL: Molecular Subtypes Based on BTK Expression Levels. Invited. 2024 Canadian CLL Research Meeting. Winnipeg, CA.
2024. Translational Research to Transformative Medicine. Invited. Shri R.J. Kinarivala Research Award from GCRI and GCS. Ahmedabad, IN.
2024. MD Anderson Cancer Center and Research-driven Patient Care. Invited. New Delhi, IN.
2024. Panel Discussion: Nutraceuticals from Lab to Clinic. Invited. 6th International Conferences on Nutraceuticals and Chronic Diseases. Chandigarh, IN.
2024. Cotton to clinic for CLL therapy. Invited. 6th International Conferences on Nutraceuticals and Chronic Diseases. Chandigarh, IN.
2022. Controversy in a dose of BTK Inhibitors in CLL. Conference. 46th Indian Cooperative Oncology Network (ICON) Conference. Virtual Meeting, IN.
2021. Dosing By Receptor Occupancy. Conference. The Right Dose: From Phase I to Clinical Practice. Virtual Meeting, US.
2020. Ibrutinib in Session 2: Proof of Concept. Conference. The First International Summit on Interventional Pharmacoeconomics. Virtual Meeting, US.
2019. Science-driven lowering of ibrutinib dose. Conference. Eleventh International Workshop on Pharmacodynamics of Anticancer Agents. Monestier, FR.
2019. Scientific rationale for lowering the dose of ibrutinib in CLL. Conference. 4th International Conference on Hematology and Bone Marrow Transplantation. Amsterdam, NL.
2019. Model Systems to Test Vecabrutinib. Conference. Sunesis Investigators’ Meeting during the 24th Congress of the European Hematological Association. Amsterdam, NL.
2019. Mitochondrial dysfunction and inhibition of mitophagy in mantle cell lymphoma lacking ATM. Conference. 18th International Ataxia-Telangiectasia Workshop: Taking a Multidisciplinary Approach. Houston, US.
2018. Ibrutinib in CLL New Dose Schedule. Conference. Annual Conference of Indian Society of Medical & Pediatric Oncology – ISMPOCON 2018. Jaipur, IN.
2017. Oxidative phosphorylation (OxPhos) inhibition as a therapeutic strategy. Conference. 17th Symposium on Purine and Pyrimidine Metabolism in Man. Gdansk, PL.
2017. Bruton’s tyrosine kinase - Protein to precision medicine. Conference. Advances in Enzymology: Implications in Health, Disease and Therapeutics. Navi Mumbai, IN.
2017. Panel Discussion: Targeting Enzymes for Therapeutics - How Close are We?. Conference. Advances in Enzymology: Implications in Health, Disease and Therapeutics. Navi Mumbai, IN.
2016. BCR Targeting in CLL – From Bench to Bedside. Conference. 57th Annual Conference of Indian Society of Haematology & Blood Transfusion. Jaipur, IN.
2016. Targeting B‐Cell Receptor Pathway in B‐cell Malignancies: What is Next?. Invited. Targeting B‐Cell Receptor Pathway in B‐cell Malignancies: What is Next?. Milano, IT.
2016. Bcl-2 inhibitor: Natural product to novel agent. Conference. Second International Conference on Natural Products Genomics and Drug Discovery - Basic and Translational Research on Cancer and Inflammation. Colombo, LK.
2016. Mechanism-Based Targeted Combination Therapy for Chronic Lymphocytic Leukemia. Conference. 8th International Conference of Contemporary Oncology. Poznań, PL.
2016. Modulation of survival proteins during PI3K pathway inhibition. Invited. Modulation of survival proteins during PI3K pathway inhibition. Bangalore, IN.
2016. Poster Session Judge: Immuno Oncology. Conference. A Conference of New Ideas in Cancer - Challenging Dogmas. Mumbai, IN.
2016. Novel PI3 kinase inhibitors: Bench to bedside. Conference. A Conference of New Ideas in Cancer - Challenging Dogmas. Mumbai, IN.
2015. Vulnerability of a subset of lung cancer to ATP analog: Role of LKB1, AMPK, and mTOR pathway. Conference. Biennial Joint Conference of ISMPO (Indian Society of Medical & Paediatric Oncology) and ISO (Indian Society of Oncology). Mumbai, IN.
2015. Novel targets in NSCLC. Conference. 3rd DSCI-MDACC Translational Cancer Research Symposium. Delhi, IN.
2015. Targeted Therapy: Development and Challenges. Conference. New Delhi, IN.
2015. Rational combinations of targeted therapy. Invited. Rational combinations of targeted therapy. Melbourne, AU.
2015. A mechanistic rationale for testing the combination of duvelisib (IPI-145) and venetoclax (ABT-199) in chronic lymphocytic leukemia. Conference. XVI International Workshop on Chronic Lymphocytic Leukaemia 2015. Sydney, AU.
2015. Underdeveloped Opportunities in CLL. Conference. Underdeveloped Opportunities in CLL. Medlow Bath, AU.
2015. PI3 Kinase Inhibition: From Bench to Bedside. Conference. 34th Annual Conference of the Indian Association for Cancer Research. Jaipur, IN.
2014. Idelalisib: First PI3K Inhibitor for B-cell Malignancies. Invited. Idelalisib: First PI3K Inhibitor for B-cell Malignancies. Delhi, US.
2014. Targeting PI3K Pathway In B-cell Malignancies. Conference. 9th SFO, 2014 International Conference of SAARC Federation of Oncologists. Gurgaon, IN.
2014. Kinome Inhibition: PI3K Delta as a Paradigm. Conference. International Symposium on Recent Trends in Cancer Research: From Om to Omics. Ahmedabad, IN.
2014. Mechanistic Approach to Ibrutinib Combinations. Conference. Summit on Practical and Emerging Trends in Chronic Lymphocytic Leukemia. Whistler, CA.
2013. Targeting Bcl-2 Family Survival Proteins: A New Concept in Chemotherapy. Invited. Targeting Bcl-2 Family Survival Proteins: A New Concept in Chemotherapy. Mumbai, IN.
2012. Targeting Apoptosis Pathways in Leukemia. Conference. Targeting Apoptosis Pathways in Leukemia. Delhi, IN.
2012. Targeting Apoptosis Pathways in Leukemia. Conference. Targeting Apoptosis Pathways in Leukemia. Kolkata, West Bengal, IN.
2012. Gossypol: A Founding Member of Bcl-2 Antagonists. Conference. Cancer Conference. Elazig, TR.
2012. Met Receptor Tyrosine Kinase. Conference. CRI Cancer Symposium on Innovative Approaches to Explore Novel Druggable Targets. Seoul.
2012. Gossypol and its Analogs induce Cell Death. Conference. RedCat Meeting 2012. Luxembourg, LU.
2012. Gossypol and its Analogs induce Cell Death. Invited. Gossypol and its Analogs induce Cell Death. Luxembourg City, LU.
2011. Microenvironment in Heme Malignancies, First AACR India Conference on New Horizons in Cancer Research: Biology to Prevention to Therapy. Conference. Microenvironment in Heme Malignancies, First AACR India Conference on New Horizons in Cancer Research: Biology to Prevention to Therapy. Gurgaon, Delhi, IN.
2011. Grant Writing - Basic/Translational AACR Career Development Workshop, First AACR India Conference on New Horizons in Cancer Research: Biology to Prevention to Therapy. Conference. Grant Writing - Basic/Translational AACR Career Development Workshop, First AACR India Conference on New Horizons in Cancer Research: Biology to Prevention to Therapy. Gurgaon, Delhi, IN.
2011. CML - Disease, drugs, and discoveries. Invited. CML - Disease, drugs, and discoveries. Guwahati, Assam, IN.
2011. Curing CML without BMT. Invited. Curing CML without BMT. Lucknow, U.P, IN.
2010. Pim Kinase in CLL. Conference. 1st International CLL Colloquium. Orlando, US.
2010. Pim Kinase Inhibition. Conference. 8th International Workshop on the Pharmacodynamics of Anticancer Agents. Hakone, JP.
2010. Myeloma - Molecular Insights and its Relevance. Conference. 5th Annual Conference: Navigating the pathway of Myeloma Disorder –An International Update. Cuttack, IN.
2010. Myeloma Therapeutics: Mechanisms of Action and Targets. Conference. 5th Annual Conference – Navigating the pathway of Myeloma Disorder –An International Update. Cuttack, IN.
2010. Mechanisms of MCL-1 increase in CLL. Conference. CLL Global Research Foundation Alliance Meeting. Barcelona, ES.
2010. Cell Death and Inflammation – Targeting Bcl-2 survival protein. Conference. Symposium on Inflammation and Cancer. Luxembourg, LU.
2009. Symposium on Recent Trends in Cancer Research, “BCl-2 antagonists: Novel therapeutic strategies”. Conference. Kolkata, IN.
2009. Microenvironment and CLL. Conference. Third International Symposium on Translational Cancer Research. Bhubaneswar, IN.
2009. BCl-2 antagonists for chronic lymphocytic leukemia. Invited. BCl-2 antagonists for chronic lymphocytic leukemia. East Delhi, Delhi, IN.
2009. New Antileukemic Nucleoside Analogs. Conference. Stockholm, SE.
2009. Targeting antiapoptotic proteins in CLL. Conference. CLL Global Research Foundation Alliance Meeting. Potsdam, DE.
2009. Nucleoside analogs for T cell diseases. Invited. Nucleoside analogs for T cell diseases. Edmonton, Alberta, CA.
2009. BCX-1777 – Forodesine. Conference. 2006…2009 Now we know T-cell Lymphomas Better. Bologna, IT.
2009. Novel Treatments for CLL. Conference. Ranbaxy International Hematology Symposium on CLL. Mumbai, Maharashtra, IN.
2008. Targeting Antiapoptotic Proteins in CLL. Conference. CLL Global Research Foundation Alliance Meeting. Lake Orta, IT.
2008. Nelarabine- Mechanism of Action for T-cell Diseases. Conference. XII International Symposium on Acute Leukemias: Satellite Symposium. Munich, DE.
2007. Novel Treatments for Leukemias – A Close Look at the Bench. Conference. Ranbaxy International Hematology Symposium on CML. Mumbai, Maharashtra, IN.
2006. Forodesine, Preclinical studies. Conference. International Meeting on T-Cell Lymphomas. Bologna, IT.
2006. Clofarabine: An effective agent for AML. Invited. Clofarabine: An effective agent for AML. Nijmegen, NL.
2006. Using Cellular Pharmacology in the Evaluation of New Agents. Conference. Annual European Hematological Society (EHA) Meeting, Satellite Symposium. Amsterdam, NL.
2006. Novel & Effective Cytotoxic Treatments for Leukemias – A Close Look at the Bench. Conference. Jaipur, Rajasthan, IN.
2005. Translational research with a targeted cytotoxic. Conference. International Symposium on Translational Research: Apoptosis & Cancer. Trivandrum, Kerala, IN.
2005. cMet as a Target for Cancer Therapy. Invited. Advanced Centre for Treatment, Reasearch and Education in Cancer (ACTREC), IN.
2005. Clofarabine in acute leukemias: Relationship between pharmacokinetics/dynamics and response to therapy. Conference. 6th International Symposium and Expert Workshops on Leukemia and Lymphoma. Amaterdam, NL.
2003. Clofarabine is active in acute leukemias: Pharmacokinetics and pharmacodynamics. Invited. Department of Medical Oncology. London, GB.
2003. Pharmacology of nucleoside analogs: Rational development of clofarabine. Conference. Annual European Hematological Society (EHA) Meeting. Lyon, FR.
2003. New strategies for the treatment of hematologic malignancies. Conference. Annual European Hematological Society (EHA) Meeting. Lyon, FR.
2003. Clofarabine in acute leukemias: Clinical success and pharmacokinetics. Conference. 11th International and 9th European Meeting on Purines and Pyrimidines. Manchester, GB.
2002. New Purine Analogs. Conference. International Workshop on New Drugs in Hematologic Malignancies. Lucerne, CH.
2002. Drug Development for Leukemias. Invited. Drug Development for Leukemias, IN.
2001. Compound GW506U78 (Nelarabine) in chronic lymphocytic leukemia. Conference. International Workshop on New Drugs in Hematologic Malignancies. Bologna, IT.
2001. Pharmacokinetics and future perspectives with Bendamustine. Conference. ECCO 11 European Cancer Congress, Hematology Forum, Bendamustine in the Treatment of Hematological Malignancies. Lisbon, PT.
1998. Prodrug of arabinosylguanine: PK/PD and clinical responses. Conference. 4th International Workshop on the Pharmacodynamics of Anticancer Agents. Dunkeld, GB.
1998. Ara-G: A new nucleoside analogue in leukemia. Conference. Third International Symposium on Drug Resistance in Leukemia and Lymphoma. Amsterdam, NL.
1997. Chlorodeoxyadenosine mediated biochemical modulation of ara-C during AML therapy. Conference. IV Pediatric Onco-Hematology Meeting. Recife, BR.
1997. Nucleoside analogs for treatment of leukemias. Conference. IV Pediatric Onco-Hematology Meeting. Recife, BR.
1997. Novel approaches for therapy of leukemias. Conference. International Symposium on Acute Leukemias VII: Experimental Approaches and Novel Therapies. Munich, DE.
1996. Clinical and pharmacological interactions of 2-CdA. Conference. XXII Congress of Brazilian Hematology and Hematotherapy. Porto Alegre, BR.
1996. Making drugs work better. Conference. Third International Conference on Leukemia, the next questions…. New Orleans, US.
1996. Cellular pharmacology. Conference. Symposium on Gemcitabine. Amsterdam, NL.
1996. Fludarabine: Actions and Apoptosis. Conference, PT.
1995. Purine nucleoside analogs: Action and apoptosis. Conference. Symposium on New Developments in the Treatment of Leukemia and Lymphoma. Zaragoza, ES.
1995. Future of purine nucleoside analogs in Hemato-oncology. Conference. National Meeting of the Spanish Society of Hematology and Hematotherapy. Symposium on New Developments in the treatment of Leukemia and Lymphoma. Zaragoza, ES.
1995. Fludarabine: Pharmacokinetics and mechanism of action. Conference. VIII Annual Meeting of the Asian Pacific Division of the International Society of Hematology. Symposium on Fludarabine. Sydney, AU.
1995. Fludara: Mechanism of action. Conference. Annual Meeting of the German and Austrian Societies of Hematology. Symposium on Fludarabine. Basel, CH.
1995. Ara-C modulation by fludarabine: A strategy to overcome resistance to ara-C. Conference. Second International Symposium. Amsterdam, NL.
1994. Research and medicines on leukemia: Combination of fludarabine and ara-C for therapy of AML. Invited. Research and medicines on leukemia: Combination of fludarabine and ara-C for therapy of AML, IN.
1994. Modulation of ara-C during therapy for patients with AML. Invited. Parel, IN.
1994. Biochemical modulation strategy to increase leukemia response. Invited. Biochemical modulation strategy to increase leukemia response, IN.
1994. Biological and biochemical modulation of arabinosylcytosine during therapy. Conference. International Conference on Acute Leukemias and Lymphomas. Suzdal, RU.
1994. Modulation of arabinosylcytosine during therapy of acute myelogenous leukemia. Conference. Modern Trends in Human Leukemia IX. St. Petersburg, RU.
1994. Metabolism and actions of difluoropurines. Conference. Workshop on Gemcitabine. Amsterdam, NL.
1994. Pharmacologic and molecular analysis of ara-C modulation by fludarabine. Conference. International Symposium on Acute Leukemias: Experimental Approaches and Management of Refractory Disease. Munster, DE.
1993. Biochemical and molecular rationales for clinical success of fludarabine and ara-C in AML. Invited. Biochemical and molecular rationales for clinical success of fludarabine and ara-C in AML. Vienna, AT.
1993. Metabolism and interactions of fludarabine. Conference. International Society of Experimental Hematology, Satellite Symposium. Rotterdam, US.
1993. Anticancer therapy. Conference. Workshop on Intracellular Monitoring of Nucleoside Analog Drugs: A new Frontier for TDM. Philadelphia, US.
1992. Successful biochemical modulation of arabinosylcytosine in leukemia therapy. Invited. Nijmegen, NL.
1992. Biochemical basis for combination therapy. Conference. Pharmacokinetics and Management of Relapsed and Refractory Disease. Munster, DE.
1992. Modulation of ara-C for therapy of AML, Prognostic Factors and Treatment Strategies. Conference. Modulation of ara-C for therapy of AML, DE.
1991. Potentiation of ara-CTP accumulation by pretreatment with F-ara-A. Invited. Solna, SE.
1991. Combination of fludarabine and ara-C for therapy of acute myelogenous leukemia. Invited. Department of Medical Oncology. London, GB.

Less

Grant & Contract Support

Date:	2025 - 2030
Title:	Deciphering the Role of Sox8 in Triggering Aggressive T-Cell Acute Lymphoblastic Leukemia in TPL2 Transgenic Mice and Pathogenesis in Humans
Funding Source:	Department of Defense
Role:	Co-I
ID:	HT942524RCRPIDA

Date:	2025 - 2030
Title:	Targeting ATM-dependent and independent mitophagy-induced cancer cell death in Lymphoma/ Blood Cancers
Funding Source:	Department of Defense
Role:	Co-I
ID:	HT942524RCRPIDA

Date:	2025 - 2027
Title:	Preclinical and clinical concepts to evaluate BTK degrader in combination
Funding Source:	AbbVie
Role:	PI

Date:	2025 - 2027
Title:	Optimization of ibrutinib dose in CLL
Funding Source:	Janssen
Role:	PI

Date:	2025 - 2027
Title:	Low-dose ibrutinib and inhibition of BCR signaling pathway
Funding Source:	Janssen Oncology
Role:	PI
ID:	Not Assigned Yet

Date:	2025 - 2029
Title:	CLL Academy - A Training Grant
Funding Source:	CLL-Global Research Foundation
Role:	PI
ID:	Not Assigned Yet

Date:	2024 - 2027
Title:	Deciphering the role of Sox8 in triggering aggressive T-cell acute lymphoblastic leukemia in TPL2 transgenic mice and pathogenesis in humans
Funding Source:	DOD/Congressionally Directed Medical Research Programs (DOD/CDMRP)
Role:	Co-I
ID:	GRANT13981128

Date:	2024 - 2026
Title:	Project 1: Understanding Mechanisms of Resistance to Targeted Therapies in Refractory CLL
Funding Source:	The University of Texas MD Anderson Cancer Center
Role:	PI

Date:	2024 - 2027
Title:	Overcoming Barriers of BTKi in CLL
Funding Source:	CLL Global Research Foundation: U.S./European Alliance
Role:	PI

Date:	2024 - 2027
Title:	Role of Ataxia Telangiectasia Mutated n mitochondrial autophagy in Cancer Character Count
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Co-I
ID:	RP240150

Date:	2023 - 2024
Title:	Project 2: Developing synergistic therapies for progressive CLL and RT
Funding Source:	The University of Texas MD Anderson Cancer Center, Moon Shots Program
Role:	Principal Investigator-MDACC

Date:	2023 - 2024
Title:	Project 3: Immune microenvironment in CLL progression and RT
Funding Source:	The University of Texas MD Anderson Cancer Center, Moon Shots Program
Role:	PI

Date:	2023 - 2026
Title:	Deciphering the role of Sox8 in triggering aggressive T-cell acute lymphoblastic leukemia in TPL2 transgenic mice and pathogenesis in humans
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Co-I
ID:	RA220093

Date:	2023 - 2026
Title:	Translational and clinical research with pirtobrutinib in chronic lymphocytic leukemia (CLL) and Richter’s transformation (RT)
Funding Source:	LOXO Eli Lily & Company
Role:	PI

Date:	2023 - 2025
Title:	A combination strategy to target pathophysiology of chronic lymphocytic leukemia (CLL)
Funding Source:	NIH/NCI
Role:	PI
ID:	R21 CA259749-01A1

Date:	2022 - 2023
Title:	Project 2: Curative Targeted Therapy of CLL
Funding Source:	The University of Texas MD Anderson Cancer Center, Moon Shots Program
Role:	Principal Investigator-MDACC

Date:	2022 - 2023
Title:	Project 1: CLL Transformation
Funding Source:	The University of Texas MD Anderson Cancer Center, Moon Shots Program
Role:	Principal Investigator-MDACC

Date:	2022 - 2027
Title:	Novel RNA-Directed Therapy for the Treatment of Acute Myeloid Leukemia
Funding Source:	NIH/NCI
Role:	Multiple PI
ID:	R01CA201496

Date:	2021 - 2022
Title:	Project 2: Biology and Targeting of 17pdel and mutant TP53 in CLL
Funding Source:	The University of Texas MD Anderson Cancer Center, Moon Shots Program
Role:	Principal Investigator-MDACC

Date:	2021 - 2022
Title:	Project 3: Pathophysiology of CLL
Funding Source:	The University of Texas MD Anderson Cancer Center, Moon Shots Program
Role:	Principal Investigator-MDACC

Date:	2021 - 2026
Title:	Novel RNA-Directed Therapy for the Treatment of Acute Myeloid Leukemia
Funding Source:	NIH/NCI
Role:	Multiple PI

Date:	2021 - 2026
Title:	Targeted combination therapy for patients with chronic lymphocytic leukemia to eradicate disease
Funding Source:	NIH/NCI
Role:	PI
ID:	1 R01 CA267895-01

Date:	2021 - 2026
Title:	Repurposing Leflunomide to Delay Progression of Smoldering Multiple Myeloma in African Americans
Funding Source:	NIH/NCI, Beckman Research Institute/City of Hope
Role:	Other Significant Contributor
ID:	R01CA253545-01A1

Date:	2021 - 2023
Title:	A combination strategy to target pathophysiology of chronic lymphocytic leukemia
Funding Source:	NIH/NCI
Role:	PI
ID:	R21

Date:	2020 - 2021
Title:	Pharmacodynamic Investigations with Brequinar
Funding Source:	Clear Creek Bio, Inc
Role:	PI

Date:	2020 - 2026
Title:	Targeting Metabolic Rewiring in CLL
Funding Source:	CLL Global Research Foundation
Role:	Mentor

Date:	2019 - 2023
Title:	Targeting McI-1 in CLL
Funding Source:	CLL Global Research Foundation: U.S./European Alliance
Role:	PI

Date:	2019 - 2022
Title:	Investigations with LOXO-305 in Chronic Lymphocytic Leukemia
Funding Source:	Loxo Oncology
Role:	PI

Date:	2018 - 2023
Title:	Transcriptomics and proteomics in CLL
Funding Source:	CLL Global Research Foundation
Role:	PI

Date:	2018 - 2020
Title:	Combined BTK and BCL2 inhibition in CLL:A non-chemotherapy therapeutic approach
Funding Source:	Andrew Sabin Family Foundation Fellows Award
Role:	Mentor

Date:	2018 - 2023
Title:	Molecular analysis and therapeutic targeting of intraclonal populations of CLL
Funding Source:	NIH/NCI
Role:	PI

Date:	2018 - 2022
Title:	Clinical and biological optimization of chronic lymphocytic leukemia therapy with ibrutinib
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	PI

Date:	2018 - 2021
Title:	Role of Ataxia telangiectasia mutated in mitochondrial autophagy in Mantle Cell Lymphoma
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Co-I
ID:	RP180532

Date:	2018 - 2021
Title:	Understanding the Role of Mcl1 in MAPK driven Tumors in TNBC
Funding Source:	American Cancer Society (ACS)
Role:	Co-I
ID:	RSG-17-205-01-TBG

Date:	2017 - 2021
Title:	A phase 1b/2 study of SNS-062 in patients with B-cell malignancies
Funding Source:	Sunesis
Role:	PI

Date:	2017 - 2020
Title:	Optimizing Therapy of Chronic Lymphocytic Leukemia with Ibrutinib
Funding Source:	Leukemia and Lymphoma Society
Role:	PI

Date:	2017 - 2020
Title:	Proteomics Profiling in Blood CLL Cells after Ibrutinib Therapy
Funding Source:	CLL Global Research Foundation
Role:	PI

Date:	2017 - 2021
Title:	Targeting the Monocyte/Macrophage Lineage as a Novel Therapeutic Strategy in CLL
Funding Source:	CLL Global Research Foundation
Role:	PI
ID:	7687

Date:	2016 - 2019
Title:	A Phase II Study of Venetoclax and Ibrutinib in Patients with CLL
Funding Source:	AbbVie Inc
Role:	PI

Date:	2016 - 2022
Title:	Novel RNA-Directed Therapy for the Treatment of Acute Myeloid Leukemia
Funding Source:	NIH/NCI
Role:	Co-PI
ID:	R01 CA201496-01A1

Date:	2016 - 2024
Title:	First-line Therapy with Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (GA-101) (iFCG) for Patients with Chronic Lymphocytic Leukemia (CLL) with Mutated IGHV gene, 2015-0281
Funding Source:	(iFCG)
Role:	PI
ID:	Award 51524

Date:	2015 - 2017
Title:	Investigations with ACP-196 in chronic lymphocytic leukemia
Funding Source:	Acerta Pharma LLC
Role:	PI

Date:	2014 - 2016
Title:	Identify and develop therapeutic partners to combine with ibrutinib and determine changes in BCR pathway anti and pro-apoptotic proteins after ibrutinib treatment (PCYC-1115)
Funding Source:	Pharmacyclics, Inc
Role:	PI

Date:	2013 - 2016
Title:	Attacking the Specific Vulnerability of LKB1-mutant NSCLC to Energy Depletion Using an ATP Mimetic
Funding Source:	The V Foundation for Cancer Research
Role:	Co-PI

Date:	2013 - 2016
Title:	Pim kinase inhibition as a therapeutic strategy for acute myeloid leukemia
Funding Source:	Leukemia and Lymphoma Society
Role:	PI
ID:	TRP Grant R6011-14

Date:	2013 - 2014
Title:	Truncated Met Receptor Tyrosine Kinase Isoforms in Myeloma
Funding Source:	Myeloma SPORE Career Development Program
Role:	Mentor

Date:	2013 - 2015
Title:	Expression of survival proteins & combination strategies during ibrutinib trials in CLL
Funding Source:	Pharmacyclics, Inc
Role:	PI

Date:	2013 - 2014
Title:	Novel Strategy to Activate Executioner Caspases in Multiple Myeloma
Funding Source:	Multiple Myeloma SPORE Developmental Research Project
Role:	PI

Date:	2013 - 2020
Title:	Development of Ibrutinib for CLL - Flagship Project
Funding Source:	The University of Texas MD Anderson Cancer Center, Moon Shots Program
Role:	PI

Date:	2013 - 2021
Title:	Project 1; Targeting Pathophysiology of CLL
Funding Source:	The University of Texas MD Anderson Cancer Center, Moon Shots Program
Role:	Principal Investigator-MDACC

Date:	2013 - 2018
Title:	Novel Strategies for CLL Treatment
Funding Source:	CLL Global Research Foundation: U.S./European Alliance
Role:	PI

Date:	2012 - 2017
Title:	Chronic Lymphocytic Leukemia Research Consortium, Project 2 - Biochemistry of Apoptosis
Funding Source:	NIH/NCI
Role:	Project Leader
ID:	PO1 CA81534-12

Date:	2012 - 2014
Title:	Targeting Nitric Oxide Production for CLL Therapy
Funding Source:	Center for Targeted Therapy
Role:	PI
ID:	CTT-TI-3D

Date:	2012 - 2014
Title:	Mechanism-Based Combinations with GS-1101 in B-cell Malignancies
Funding Source:	Gilead Sciences, Inc
Role:	PI

Date:	2012 - 2013
Title:	Expression and Activation of Procaspase 3 in Chronic Lymphocytic Leukemia Cells
Funding Source:	Vanquish Oncology
Role:	PI

Date:	2012 - 2013
Title:	Investigation of Biomarkers for Pim Kinase Inhibition by AZD1208 in AML
Funding Source:	AstraZeneca
Role:	PI

Date:	2011 - 2012
Title:	A Phase Ia/Ib, Open Label, Multicenter, Two Part Study to Assess the Safety, Tolerability Pharmacokinetics and Efficacy of AZD1208
Funding Source:	AstraZeneca
Role:	Co-PI
ID:	CS2012-00035828

Date:	2011 - 2015
Title:	Targeting Met Tyrosine Kinase in Myeloma
Funding Source:	Leukemia and Lymphoma Society
Role:	PI
ID:	TRG6017-12

Date:	2011 - 2013
Title:	Expression of Metabolic Proteins and Nucleoside Transporters in AML Patients from Study SGI-110-01 from Other Centers
Funding Source:	SuperGen, Inc
Role:	PI

Date:	2011 - 2013
Title:	Expression of Metabolic Proteins and Nucleoside Transporters in AML Patients from Study SGI-110-01 at MDACC
Funding Source:	SuperGen, Inc
Role:	PI

Date:	2011 - 2014
Title:	Therapeutic Applications of 8-Substituted Adenosine Analogs in Lymphomas
Funding Source:	American Cancer Society Postdoctoral Fellowship
Role:	Mentor
ID:	118818

Date:	2011 - 2013
Title:	Targeting Met Tyrosine Kinase in Multiple Myeloma
Funding Source:	Myeloma SPORE Developmental Research Project
Role:	PI

Date:	2011 - 2013
Title:	Truncated Met Tyrosine Kinase Isoforms in Myeloma
Funding Source:	Myeloma SPORE Career Development Project
Role:	Mentor

Date:	2011 - 2012
Title:	Expression of Metabolic Proteins in AML
Funding Source:	SuperGen
Role:	PI

Date:	2010 - 2013
Title:	Pim Kinase Inhibition as a Therapeutic Strategy for AML
Funding Source:	Leukemia and Lymphoma Society
Role:	PI
ID:	TRG6233-11

Date:	2010 - 2011
Title:	Pim Kinase Inhibition as a Therapeutic Strategy for Acute Myeloid Leukemia
Funding Source:	Leukemia SPORE Career Development Project
Role:	Mentor

Date:	2010 - 2014
Title:	A Pharmacokinetic and Pharmacodynamic Study to Evaluate the Safety and Feasibility of Continuous Infusion Nelarabine in Patients with Relapsed/Refractory Lymphoid Malignancies
Funding Source:	GlaxoSmithKline
Role:	PI

Date:	2009 - 2012
Title:	Effect of Microenvironment on Mcl-1 in CLL Cells
Funding Source:	CLL Global Research Foundation
Role:	PI

Date:	2009 - 2012
Title:	Project 2: Development of 8-Cl-Adenosine
Funding Source:	Lymphoma SPORE
Role:	PI
ID:	P30 CA136411

Date:	2009 - 2012
Title:	A Phase I Clinical Trial of 8-Chloroadenosine in Patients with Chronic Leukemia
Funding Source:	Commonwealth Foundation Grant Award
Role:	Co-PI

Date:	2009 - 2011
Title:	8-Cl-Ado for Treatment of CLL
Funding Source:	NIH/NCI
Role:	PI
ID:	1R21 CA112907

Date:	2009 - 2009
Title:	Nucleoside, Nucleotides, and Oligonucleotides
Funding Source:	Gordon Research Conference
Role:	PI
ID:	1R13-CA139647-01

Date:	2008 - 2013
Title:	Phase I Clinical and Pharmacodynamic Investigation of 8-Cl-Ado
Funding Source:	Food and Drug Administration (FDA)
Role:	PI
ID:	1R01-003550

Date:	2008 - 2010
Title:	Minority Graduate Student Supplement (Fabiola Gomez)
Funding Source:	NIH/NCI
Role:	PI
ID:	NIH P50-SPORE-CA100632

Date:	2008 - 2012
Title:	Therapeutic Strategies to Alter Gene Expression in Breast Cancer
Funding Source:	Susan G. Komen Career Catalyst Award CCR
Role:	Mentor
ID:	KG080366

Date:	2008 - 2010
Title:	Targeting Met Tyrosine Kinase in Multiple Myeloma
Funding Source:	Center for Targeted Therapy Disease
Role:	PI

Date:	2008 - 2013
Title:	Project 3: Pharmacodynamic Analysis of Sapacitabine Therapy
Funding Source:	Leukemia SPORE
Role:	Co-I
ID:	P50 CA100632

Date:	2008 - 2013
Title:	Targeting Anti-apoptotic Proteins in CLL
Funding Source:	US/European Alliance for the Therapy of CLL
Role:	PI
ID:	CLL Global Research Foundation

Date:	2007 - 2010
Title:	Minority Graduate Student Supplement (Cornel Phillips)
Funding Source:	NIH/NCI
Role:	PI
ID:	RO1-CA85915

Date:	2007 - 2008
Title:	Preclinical Development of Bendamustine
Funding Source:	Cephalon, Inc
Role:	Principal Investigator-MDACC

Date:	2007 - 2008
Title:	Forodesine-induced Apoptosis of CLL B Cells: Effect of the Microenvironment
Funding Source:	MundiPharma International ltd
Role:	Principal Investigator-MDACC

Date:	2007 - 2008
Title:	Preclinical Studies with Gossypol
Funding Source:	Bioenvision Ltd
Role:	Principal Investigator-MDACC

Date:	2006 - 2009
Title:	BLyS-Gelonin: A Targeted Therapeutics for CLL
Funding Source:	Leukemia and Lymphoma Society
Role:	PI

Date:	2005 - 2011
Title:	Adenosine Analogs: Therapeutics for Hematologic Cancers
Funding Source:	NIH/NCI
Role:	PI
ID:	R01 CA85915

Date:	2005 - 2007
Title:	Transcription Inhibition to Target CLL
Funding Source:	CLL Global Research Foundation
Role:	PI

Date:	2004 - 2007
Title:	DNA Independent Strategy to Target CLL
Funding Source:	Leukemia & Lymphoma Society
Role:	PI
ID:	6208-05

Date:	2003 - 2004
Title:	Aventis Drug Development Award
Funding Source:	Private Agency
Role:	PI

Date:	2003 - 2008
Title:	Project 3: Concerted Blockade of Oncoprotein Activity
Funding Source:	SPORE
Role:	Co-PI
ID:	CA100632

Date:	2003 - 2005
Title:	Clofarabine: Cytarabine Activation for Leukemia Response
Funding Source:	NIH
Role:	Co-PI
ID:	CA101354

Date:	2003 - 2008
Title:	Phase I Studies of Targeted Anti-Cancer Therapy
Funding Source:	NIH/NCI
Role:	Co-I
ID:	CA62461

Date:	2003 - 2004
Title:	Mechanism Based Combination for Treatment of Acute Myelogenous Leukemia
Funding Source:	Golfers Against Cancer
Role:	PI

Date:	2002 - 2005
Title:	Phase II Clinical and Pharmacodynamic Investigation of Clofarabine in Leukemia
Funding Source:	Food and Drug Administration (FDA)
Role:	Pharmacology Portion-Principal Investigator
ID:	FDA- FD-R-002127

Date:	2002 - 2006
Title:	Preclinical Investigations with BCX-1777
Funding Source:	BioCryst Pharmaceuticals Inc
Role:	PI

Date:	2001 - 2006
Title:	Development of Fludarabine
Funding Source:	Schering AG
Role:	Co-I

Date:	2001 - 2005
Title:	Metabolic Strategies to Expand the Use of Nipent
Funding Source:	SuperGen, Inc
Role:	PI

Date:	2001 - 2005
Title:	Expression of Metabolic Proteins in AML
Funding Source:	SuperGen, Inc
Role:	PI

Date:	2000 - 2006
Title:	Pharmacokinetics and Pharmacodynamics in AML, William Plunkett Project Leader
Funding Source:	NIH
Role:	Co-I
ID:	CA55164

Date:	1998 - 2007
Title:	Biochemical Strategies to Increase Leukemia Response
Funding Source:	NIH/NCI
Role:	PI
ID:	NIH RO1-CA57629

Selected Publications

Peer-Reviewed Articles

Tantawy, S, Aslan, B, Manyam, GC, Iles, LR, Timofeeva, N, Singh, N, Jain, N, Ferrajoli, A, Thompson, PA, Patel, KP, Desikan, SP, Wierda, WG, Gandhi, VV. Pharmacological profiling in CLL patients during pirtobrutinib therapy and disease progression. Blood Cancer Journal 15(1), 2025. e-Pub 2025. PMID: 41145426.
Brown JR, Nguyen B, Desikan SP, Won H, Tantawy SI, McNeely SC, Marella N, Randeria HS, Hanson LM, Parker A, Calado Botelho S, Woyach JA, Patel K, Tam CS, Eyre TA, Cheah CY, Shah NN, Ghia P, Jurczak W, Balbas M, Nair BC, Abada PB, Wang C, Wang D, Roeker LE, Gandhi V, Wierda WG. Genomic Determinants of Response and Resistance to Pirtobrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia. Blood, 2025. e-Pub 2025. PMID: 41055698.
Mughees, M, Tacam, MJ, Tan, AW, Pitner, MK, Iles, LR, Hu, XD, Schlee Villodre, E, Debeb, BG, Kogawa, T, Lim, B, Layman, RM, Woodward, W, Ueno, NT, Tripathy, D, Krishnamurthy, S, Qi, Y, Pusztai, L, Wang, J, Gandhi, VV, Bartholomeusz, G, Bartholomeusz, C. Inhibition of MCL-1 and MEK Overcomes MEK Inhibitor Resistance in Triple-Negative and Inflammatory Breast Cancers. Molecular cancer therapeutics 24(9):1453-1465, 2025. e-Pub 2025. PMID: 40358476.
Chen LS, Bose P, Qiao W, Jiang Y, Wu Q, Cruz ND, Keating MJ, Gandhi V. A pilot study of lower doses of ibrutinib: patient body weight does not correlate with plasma ibrutinib levels during therapy. Leuk Lymphoma 66(6):1166-1168, 2025. e-Pub 2025. PMID: 39921535.
Zhang R, Khare P, Banerjee P, Ivan C, Schneider S, Barbaglio F, Clise-Dwyer K, Jensen VB, Thompson E, Mendoza M, Chiorazzi N, Chen S, Yan XJ, Jain N, Ghia P, Caligaris-Cappio F, Mendonsa R, Kasimsetty S, Swoboda R, Bayraktar R, Wierda W, Gandhi V, Calin GA, Keating MJ, Sabrina Bertilaccio MT. The DLEU2/miR-15a/miR-16-1 cluster shapes the immune microenvironment of chronic lymphocytic leukemia. Blood Cancer Journal 14(1), 2024. e-Pub 2024. PMID: 39438453.
Kismali G, Manyam G, Jain N, Ivan C, Lamothe B, Ayres ML, Iles LR, Wierda WG, Gandhi V. Transcriptomic clustering of Chronic lymphocytic leukemia: molecular subtypes based on Bruton’s tyrosine kinase expression levels. Blood Cancer Journal 14(1):220, 2024. e-Pub 2024. PMID: 39695112.
Aslan B, Manyam G, Iles LR, Tantawy SI, Desikan SP, Wierda WG, Gandhi V. Transcriptomic and proteomic differences in BTK-WT and BTK-mutated CLL and their changes during therapy with pirtobrutinib. Blood Advances 8(17):4487-4501, 2024. e-Pub 2024. PMID: 38968154.
Mabel P-O, Romano G, Farris DP, Gandhi V, Wistuba II, Tillman RE, Udan R, Mangahas P, Soundararajan R. A structured curriculum supporting biomedical trainees' transition into independent academic positions and early career success. BMC Med Educ 24(1):379, 2024. e-Pub 2024. PMID: 38589919.
Pullarkat V, Chen LS, Palmer J, Zhang J, Synold TW, Buettner R, Truong Nguyen LX, Marcucci G, Tsai NC, Wang Y, O'Hearn J, Gandhi V, Rosen ST. A phase 1 trial of 8-chloro-adenosine in relapsed/refractory acute myeloid leukemia: an evaluation of safety and pharmacokinetics. Cancer 130(5):727-739, 2024. e-Pub 2024. PMID: 37897709.
Tantawy SI, Timofeeva N, Hernandez A, Sarkar A, Gandhi V. Decoding the Mechanism behind MCL-1 Inhibitors: A Pathway to Understanding MCL-1 Protein Stability. Oncotarget 14(1):653-655, 2023. e-Pub 2023. PMID: 37343064.
Boddu PC, Senapati J, Ravandi-Kashani F, Jabbour EJ, Jain N, Ayres M, Chen Y, Keating MJ, Kantarjian HM, Gandhi V, Kadia TM. A phase 1 study to evaluate the safety, pharmacology, and feasibility of continuous infusion nelarabine in patients with relapsed and/or refractory lymphoid malignancies. Cancer 129(4):580-589, 2023. e-Pub 2023. PMID: 36448227.
Tantawy SI, Sarkar A, Hubner S, Tan Z, Wierda WG, Eldeib A, Zhang S, Kornblau S, Gandhi V. Mechanisms of MCL-1 protein stability induced by MCL-1 antagonists in B-cell malignancies. Clin Cancer Res 29(2):446-457, 2023. e-Pub 2023. PMID: 36346691.
Timofeeva N, Ayres ML, Baran N, Santiago-O'Farrill JM, Bildik G, Lu Z, Konopleva M, Gandhi V. Preclinical investigations of the efficacy of the glutaminase inhibitor CB-839 alone and in combinations in chronic lymphocytic leukemia. Front Oncol 13:1161254, 2023. e-Pub 2023. PMID: 37228498.
Sexauer AN, Alexe G, Gustafsson K, Zanetakos E, Milosevic J, Ayres M, Gandhi V, Pikman Y, Stegmaier K, Sykes DB. DHODH: a promising target in the treatment of T-cell acute lymphoblastic leukemia. Blood Adv 7(21):6685-6701, 2023. e-Pub 2023. PMID: 37648673.
Timofeeva, N, Jain, N, Irajizad, E, Aslan, B, Katayama, H, Cai, Y, Ayres, M, Iles, LR, Vykoukal, JV, Dennison, JB, Hanash, S, Wierda, WG, Gandhi, VV. CLL-532 Changes in Proteome of CLL (Chronic Lymphocytic Leukemia) Lymphocytes During Investigator-Initiated Trial of Ibrutinib Alone and in Combination With Venetoclax in Treatment-Naïve Patients With CLL. Clinical Lymphoma, Myeloma and Leukemia 22:S283, 2022. e-Pub 2022. PMID: 36163901.
Demarest JF, Kienle M, Boytz R, Ayres M, Kim EJ, Patten JJ, Chung D, Gandhi V, Davey RA, Sykes DB, Shohdy N, Pottage JC, Kumar VS. Brequinar and Dipyridamole in Combination Exhibits Synergistic Antiviral Activity Against SARS-CoV-2 in vitro: Rationale for a host-acting antiviral treatment strategy for COVID-19. Antiviral Res 206:105403, 2022. e-Pub 2022. PMID: 36041646.
Tettamanti S, Rotiroti MC, Giordano Attianese GMP, Arcangeli S, Zhang R, Banerjee P, Galletti G, McManus S, Mazza M, Nicolini F, Martinelli G, Ivan C, Veliz Rodriguez T, Barbaglio F, Scarfò L, Ponzoni M, Wierda W, Gandhi V, Keating M, Biondi A, Caligaris-Cappio F, Biagi E, Ghia P, Bertilaccio MTS. Lenalidomide enhances CD23.CAR T cell therapy in chronic lymphocytic leukemia. Leuk Lymphoma 63(7):1-14, 2022. e-Pub 2022. PMID: 35259043.
Aslan B, Kismali G, Iles LR, Manyam GC, Ayres ML, Chen LS, Gagea M, Bertilaccio MTS, Wierda WG, Gandhi V. Pirtobrutinib inhibits wild-type and mutant Bruton's tyrosine kinase-mediated signaling in chronic lymphocytic leukemia. Blood Cancer J 12(5):80, 2022. e-Pub 2022. PMID: 35595730.
Hoang DH, Morales C, Rodriguez IR, Valerio M, Guo J, Chen MH, Wu X, Horne D, Gandhi V, Chen LS, Zhang B, Pullarkat V, Rosen ST, Marcucci G, Buettner R, Nguyen LXT. Synergy of Venetoclax and 8-Chloro-Adenosine in AML: The Interplay of rRNA Inhibition and Fatty Acid Metabolism. Cancers (Basel) 14(6), 2022. e-Pub 2022. PMID: 35326597.
Yi X, Jain N, Iles LR, Ayres ML, Wierda WG, Gandhi V. Targeting Mcl-1 by AMG-176 during ibrutinib and venetoclax therapy in chronic lymphocytic leukemia. Front Oncol 12:833714, 2022. e-Pub 2022. PMID: 35273915.
Galan-Cobo A, Stellrecht CM, Yilmaz E, Yang C, Qian Y, Qu X, Akhter I, Ayres ML, Fan Y, Tong P, Diao L, Ding J, Giri U, Gudikote J, Nilsson M, Wierda WG, Wang J, Skoulidis F, Minna JD, Gandhi V, Heymach JV. Enhanced vulnerability of LKB1-deficient NSCLC to disruption of ATP pools and redox homeostasis by 8-Cl-Ado. Mol Cancer Res 20(2):280-292, 2022. e-Pub 2022. PMID: 34654720.
Aslan B, Hubner SE, Fox JA, Taverna P, Wierda WG, Kornblau SM, Gandhi V. Vecabrutinib inhibits B-cell receptor signal transduction in chronic lymphocytic leukemia cell types with wild-type or mutant Bruton's tyrosine kinase. Haematologica 107(1):292-297, 2022. e-Pub 2022. PMID: 34498444.
Teakell S, Chen LS, Stellrecht CM, Gandhi V. The role of p53 and p21 on 8-chloro-adenosine-induced cellular response. Nucleosides Nucleotides Nucleic Acids 41(12):1359-1374, 2022. e-Pub 2022. PMID: 35227162.
Jain N, Thompson P, Burger J, Ferrajoli A, Takahashi K, Estrov Z, Borthakur G, Bose P, Kadia T, Pemmaraju N, Sasaki K, Konopleva M, Jabbour E, Garg N, Wang X, Kanagal-Shamanna R, Patel K, Wang W, Jorgensen J, Wang S, Lopez W, Ayala A, Plunkett W, Gandhi V, Kantarjian H, O'Brien S, Keating M, Wierda WG. Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations. Leukemia 35(12):3421-3429, 2021. e-Pub 2021. PMID: 34007049.
Jain N, Keating M, Thompson P, Ferrajoli A, Burger JA, Borthakur G, Takahashi K, Estrov Z, Sasaki K, Fowler N, Kadia T, Konopleva M, Alvarado Y, Yilmaz M, DiNardo C, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Kanagal-Shamanna R, Patel K, Wang W, Jorgensen J, Wang SA, Garg N, Wang X, Wei C, Cruz N, Ayala A, Plunkett W, Kantarjian H, Gandhi V, Wierda WG. Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia: A Nonrandomized Phase 2 Trial. JAMA Oncol 7(8):1213-1219, 2021. e-Pub 2021. PMID: 34110383.
Aslan B, Kismali G, Chen LS, Iles LR, Mahendra M, Peoples M, Gagea M, Fowlkes NW, Zheng X, Wang J, Vellano CP, Marszalek JR, Bertilaccio MTS, Gandhi V. Development and characterization of prototypes for in vitro and in vivo mouse models of ibrutinib-resistant CLL. Blood Adv 5(16):3134-3146, 2021. e-Pub 2021. PMID: 34424317.
Buettner R, Nguyen LXT, Morales C, Chen MH, Wu X, Chen LS, Hoang DH, Hernandez Vargas S, Pullarkat V, Gandhi V, Marcucci G, Rosen ST. Targeting the metabolic vulnerability of acute myeloid leukemia blasts with a combination of venetoclax and 8-chloro-adenosine. J Hematol Oncol 14(1):70, 2021. e-Pub 2021. PMID: 33902674.
Sarkar A, Stellrecht CM, Vangapandu HV, Ayres M, Kaipparettu BA, Park JH, Balakrishnan K, Burks JK, Pandita TK, Hittelman WN, Neelapu SS, Gandhi V. Ataxia telangiectasia mutated interacts with Parkin and induces mitophagy independent of kinase activity. Evidence from mantle cell lymphoma. Haematologica 106(2):495-512, 2021. e-Pub 2021. PMID: 32029507.
Sarkar A, Gandhi V. Activation of ATM kinase by ROS generated during ionophore-induced mitophagy in human T and B cell malignancies. Mol Cell Biochem 476(1):417-423, 2021. e-Pub 2021. PMID: 32996079.
Yi X, Sarkar A, Kismali G, Aslan B, Ayres M, Iles LR, Keating MJ, Wierda WG, Long JP, Bertilaccio MTS, Gandhi V. AMG-176, an Mcl-1 antagonist, shows preclinical efficacy in chronic lymphocytic leukemia. Clin Cancer Res 26(14):3856-3867, 2020. e-Pub 2020. PMID: 31937611.
Banerjee P, Zhang R, Ivan C, Galletti G, Clise-Dwyer K, Barbaglio F, Scarfò L, Aracil M, Klein C, Wierda W, Plunkett W, Caligaris-Cappio F, Gandhi V, Keating MJ, Bertilaccio MTS. Trabectedin Reveals a Strategy of Immunomodulation in Chronic Lymphocytic Leukemia. Cancer Immunol Res 7(12):2036-2051, 2019. e-Pub 2019. PMID: 31530560.
Chen LS, Keating MJ, Wierda WG, Gandhi V. Induction of apoptosis by MCL-1 inhibitors in chronic lymphocytic leukemia cells. Leuk Lymphoma 60(12):1-4, 2019. e-Pub 2019. PMID: 31161836.
Buettner R, Nguyen LXT, Kumar B, Morales C, Liu C, Chen LS, Pemovska T, Synold TW, Palmer J, Thompson R, Li L, Hoang DH, Zhang B, Ghoda L, Kowolik C, Kontro M, Leitch C, Wennerberg K, Yu X, Chen CC, Horne D, Gandhi V, Pullarkat V, Marcucci G, Rosen ST. 8-chloro-adenosine activity in FLT3-ITD acute myeloid leukemia. J Cell Physiol 234(9):16295-16303, 2019. e-Pub 2019. PMID: 30770553.
Bose P, Chen LS, Gandhi V. Ibrutinib dose and clinical outcome in chronic lymphocytic leukemia - learning from the 'real world'. Leuk Lymphoma 60(7):1603-1605, 2019. e-Pub 2019. PMID: 30724681.
Galan-Cobo A, Sitthideatphaiboon P, Qu X, Poteete A, Pisegna MA, Tong P, Chen PH, Boroughs LK, Rodriguez MLM, Zhang W, Parlati F, Wang J, Gandhi V, Skoulidis F, DeBerardinis RJ, Minna JD, Heymach JV. LKB1 and KEAP1/NRF2 pathways cooperatively promote metabolic reprogramming with enhanced glutamine dependence in KRAS-mutant lung adenocarcinoma. Cancer Res 79(13):3251-3267, 2019. e-Pub 2019. PMID: 31040157.
Jain N, Keating M, Thompson P, Ferrajoli A, Burger J, Borthakur G, Takahashi K, Estrov Z, Fowler N, Kadia T, Konopleva M, Alvarado Y, Yilmaz M, DiNardo C, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Sasaki K, Kanagal-Shamanna R, Patel K, Jorgensen J, Garg N, Wang X, Sondermann K, Cruz N, Wei C, Ayala A, Plunkett W, Kantarjian H, Gandhi V, Wierda W. Ibrutinib and Venetoclax for First-Line Treatment of CLL. N Engl J Med 380(22):2095-2103, 2019. e-Pub 2019. PMID: 31141631.
Cervantes-Gomez F, Stellrecht CM, Ayres ML, Keating MJ, Wierda WG, Gandhi V. PIM kinase inhibitor, AZD1208, inhibits protein translation and induces autophagy in primary chronic lymphocytic leukemia cells. Oncotarget 10(29):2793-2809, 2019. e-Pub 2019. PMID: 31073371.
Chen LS, Bose P, Cruz ND, Jiang Y, Wu Q, Thompson PA, Feng S, Kroll MH, Qiao W, Huang X, Jain N, Wierda WG, Keating MJ, Gandhi V. A pilot study of lower doses of ibrutinib in patients with chronic lymphocytic leukemia. Blood 132(21):2249-2259, 2018. e-Pub 2018. PMID: 30254130.
Chen W, Fan H, Balakrishnan K, Wang Y, Sun H, Fan Y, Gandhi V, Arnold LA, Peng X. Discovery and Optimization of Novel Hydrogen Peroxide Activated Aromatic Nitrogen Mustard Derivatives as Highly Potent Anticancer Agents. J Med Chem 61(20):9132-9145, 2018. e-Pub 2018. PMID: 30247905.
Elsayed AH, Cao X, Crews KR, Gandhi V, Plunkett W, Rubnitz JE, Ribeiro RC, Pounds SB, Lamba JK. Comprehensive Ara-C SNP score predicts leukemic cell intracellular ara-CTP levels in pediatric acute myeloid leukemia patients. Pharmacogenomics 19(14):1101-1110, 2018. e-Pub 2018. PMID: 30088438.
Vangapandu HV, Chen H, Wierda WG, Keating MJ, Korkut A, Gandhi V. Proteomics profiling identifies induction of caveolin-1 in chronic lymphocytic leukemia cells by bone marrow stromal cells. Leuk Lymphoma 59(6):1-12, 2018. e-Pub 2018. PMID: 28971726.
Cortes J, Tamura K, DeAngelo DJ, de Bono J, Lorente D, Minden M, Uy GL, Kantarjian H, Chen LS, Gandhi V, Godin R, Keating K, McEachern K, Vishwanathan K, Pease JE, Dean E. Phase I studies of AZD1208, a proviral integration Moloney virus kinase inhibitor in solid and haematological cancers. Br J Cancer 118(11):1425-1433, 2018. e-Pub 2018. PMID: 29765150.
Vangapandu HV, Alston B, Morse J, Ayres ML, Wierda WG, Keating MJ, Marszalek JR, Gandhi V. Biological and Metabolic Effects of IACS-010759, an OxPhos Inhibitor, on Chronic Lymphocytic Leukemia Cells. Oncotarget 9(38):24980-24991, 2018. e-Pub 2018. PMID: 29861847.
Short NJ, Kantarjian H, Ravandi F, Huang X, Xiao L, Garcia-Manero G, Plunkett W, Gandhi V, Sasaki K, Pemmaraju N, Daver NG, Borthakur G, Jain N, Konopleva M, Estrov Z, Kadia TM, Wierda WG, DiNardo CD, Brandt M, O'Brien SM, Cortes JE, Jabbour E. A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia. Leuk Lymphoma 59(4):813-820, 2018. e-Pub 2018. PMID: 28718728.
Patel VK, Lamothe B, Ayres ML, Gay J, Cheung JP, Balakrishnan K, Ivan C, Morse J, Nelson M, Keating MJ, Wierda WG, Marszalek JR, Gandhi V. Pharmacodynamics and Proteomic Analysis of Acalabrutinib Therapy: Similarity of On-Target Effects to Ibrutinib and Rationale for Combination Therapy. Leukemia 32(4):920-930, 2018. e-Pub 2018. PMID: 29099493.
Abou Dalle I, Cortes JE, Pinnamaneni P, Lamothe B, Diaz Duque A, Randhawa J, Pemmaraju N, Jabbour E, Ferrajoli A, Wierda WG, Estrov Z, Konopleva M, Ravandi F, Alvarado Y, Borthakur G, Gandhi V, Kantarjian HM. A Pilot Phase II Study of Erlotinib for the Treatment of Patients with Relapsed/Refractory Acute Myeloid Leukemia. Acta Haematol 140(1):30-39, 2018. e-Pub 2018. PMID: 30071517.
Vangapandu HV, Havranek O, Ayres ML, Kaipparettu BA, Balakrishnan K, Wierda WG, Keating MJ, Davis RE, Stellrecht CM, Gandhi V. B-cell Receptor Signaling Regulates Metabolism in Chronic Lymphocytic Leukemia. Mol Cancer Res 15(12):1692-1703, 2017. e-Pub 2017. PMID: 28835371.
Jabbour E, Short NJ, Ravandi F, Huang X, Xiao L, Garcia-Manero G, Plunkett W, Gandhi V, Sasaki K, Pemmaraju N, Daver NG, Borthakur G, Jain N, Konopleva M, Estrov Z, Kadia TM, Wierda WG, DiNardo CD, Brandt M, O'Brien SM, Cortes JE, Kantarjian H. A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia. Cancer 123(22):4430-4439, 2017. e-Pub 2017. PMID: 28708931.
Vangapandu HV, Ayres ML, Bristow CA, Wierda WG, Keating MJ, Balakrishnan K, Stellrecht CM, Gandhi V. The Stromal Microenvironment Modulates Mitochondrial Oxidative Phosphorylation in Chronic Lymphocytic Leukemia Cells. Neoplasia 19(10):762-771, 2017. e-Pub 2017. PMID: 28863345.
Stellrecht CM, Chen LS, Ayres ML, Dennison JB, Shentu S, Chen Y, Keating MJ, Wierda WG, Gandhi V. Chlorinated adenosine analogue induces AMPK and autophagy in chronic lymphocytic leukaemia cells during therapy. Br J Haematol 179(2):266-271, 2017. e-Pub 2017. PMID: 28737232.
Patel VM, Balakrishnan K, Douglas M, Tibbitts T, Xu EY, Kutok JL, Ayers M, Sarkar A, Guerrieri R, Wierda WG, O'Brien S, Jain N, Stern HM, Gandhi V. Duvelisib treatment is associated with altered expression of apoptotic regulators that helps in sensitization of chronic lymphocytic leukemia cells to venetoclax (ABT-199). Leukemia 31(9):1872-1881, 2017. e-Pub 2017. PMID: 28017967.
Bose P, Gandhi V, Konopleva M. Pathways and mechanisms of venetoclax resistance. Leuk Lymphoma 58(9):1-17, 2017. e-Pub 2017. PMID: 28140720.
Patel V, Balakrishnan K, Bibikova E, Ayres M, Keating MJ, Wierda WG, Gandhi V. Comparison of Acalabrutinib, A Selective Bruton Tyrosine Kinase Inhibitor, with Ibrutinib in Chronic Lymphocytic Leukemia Cells. Clin Cancer Res 23(14):3734-3743, 2017. e-Pub 2017. PMID: 28034907.
Wang Y, Fan H, Balakrishnan K, Lin Z, Cao S, Chen W, Fan Y, Guthrie QA, Sun H, Teske KA, Gandhi V, Arnold LA, Peng X. Hydrogen peroxide activated quinone methide precursors with enhanced DNA cross-linking capability and cytotoxicity towards cancer cells. Eur J Med Chem 133:197-207, 2017. e-Pub 2017. PMID: 28388522.
Baljevic M, Zaman S, Baladandayuthapani V, Lin YH, de Partovi CM, Berkova Z, Amini B, Thomas SK, Shah JJ, Weber DM, Fu M, Cleeland CS, Wang XS, Stellrecht CM, Davis RE, Gandhi V, Orlowski RZ. Phase II study of the c-MET inhibitor tivantinib (ARQ 197) in patients with relapsed or relapsed/refractory multiple myeloma. Ann Hematol(6):977-985, 2017. e-Pub 2017. PMID: 28337527.
Modi P, Balakrishnan K, Yang Q, Wierda WG, Keating MJ, Gandhi V. Idelalisib and bendamustine combination is synergistic and increases DNA damage response in chronic lymphocytic leukemia cells. Oncotarget 8(10):16259-16274, 2017. e-Pub 2017. PMID: 28187444.
Jain N, Balakrishnan K, Ferrajoli A, O'Brien SM, Burger JA, Kadia TM, Cortes JE, Ayres ML, Tambaro FP, Keating MJ, Gandhi V, Wierda WG. A Phase I-II Trial of Fludarabine, Bendamustine, and Rituximab (FBR) in Previously Treated Patients with CLL. Oncotarget(13):22104-22112, 2017. e-Pub 2017. PMID: 27655665.
Yang Q, Chen LS, Ha MJ, Do KA, Neelapu SS, Gandhi V. Idelalisib impacts cell growth through inhibiting translation regulatory mechanisms in mantle cell lymphoma. Clin Cancer Res 23(1):181-192, 2017. e-Pub 2017. PMID: 27342398.
Yang Q, Modi P, Korkut A, Fernandes SM, Hanna J, Brown JR, Gandhi V. Changes in Bcl-2 Family Protein Profile During Idelalisib Therapy Mimic Those During Duvelisib Therapy in Chronic Lymphocytic Leukemia Lymphocytes. JCO Precis Oncol 1, 2017. e-Pub 2017. PMID: 32913964.
Chen LS, Yang JY, Liang H, Cortes JE, Gandhi V. Protein profiling identifies mTOR pathway modulation and cytostatic effects of Pim kinase inhibitor, AZD1208, in acute myeloid leukemia. Leuk Lymphoma 57(12):1-11, 2016. e-Pub 2016. PMID: 27054578.
Mendes VIS, Bartholomeusz GA, Ayres M, Gandhi V, Salvador JAR. Synthesis and cytotoxic activity of novel A-ring cleaved ursolic acid derivatives in human non-small cell lung cancer cells. Eur J Med Chem 123:317-331, 2016. e-Pub 2016. PMID: 27484517.
Bose P, Gandhi V, Keating MJ. Pharmacokinetic and pharmacodynamic evaluation of ibrutinib for the treatment of chronic lymphocytic leukemia: rationale for lower doses. Expert Opin Drug Metab Toxicol 12(11):1381-1392, 2016. e-Pub 2016. PMID: 27686109.
Phillip CJ, Zaman S, Shentu S, Balakrishnan K, Zhang J, Baladandayuthapani V, Taverna P, Redkar S, Wang M, Stellrecht CM, Gandhi V. Erratum to: Targeting MET kinase with the small-molecule inhibitor amuvatinib induces cytotoxicity in primary myeloma cells and cell lines. J Hematol Oncol 9(1):110, 2016. e-Pub 2016. PMID: 27737688.
Lamothe B, Wierda WG, Keating MJ, Gandhi V. Carfilzomib triggers cell death in chronic lymphocytic leukemia by inducing proapoptotic and endoplasmic reticulum stress responses. Clin Cancer Res 22(18):4712-26, 2016. e-Pub 2016. PMID: 27026200.
Cervantes-Gomez F, Kumar Patel V, Bose P, Keating MJ, Gandhi V. Decrease in total protein level of Bruton's tyrosine kinase during ibrutinib therapy in chronic lymphocytic leukemia lymphocytes. Leukemia 30(8):1803-4, 2016. e-Pub 2016. PMID: 27198052.
Balakrishnan K, Fu M, Onida F, Wierda WG, Keating MJ, Gandhi V. Reactivation of smac-mediated apoptosis in chronic lymphocytic leukemia cells: mechanistic studies of smac mimetic. Oncotarget 7(26):39458-39472, 2016. e-Pub 2016. PMID: 27223062.
Cervantes-Gomez F, Lavergne B, Keating MJ, Wierda WG, Gandhi V. Combination of Pim kinase inhibitors and Bcl-2 antagonists in chronic lymphocytic leukemia cells. Leuk Lymphoma 57(2):436-444, 2016. e-Pub 2016. PMID: 26088877.
Sarkar A, Balakrishnan K, Chen J, Patel V, Neelapu SS, McMurray JS, Gandhi V. Molecular evidence of Zn chelation of the procaspase activating compound B-PAC-1 in B cell lymphoma. Oncotarget 7(3):3461-76, 2016. e-Pub 2016. PMID: 26658105.
Patel V, Keating MJ, Wierda WG, Gandhi V. Preclinical combination of TP-0903, an AXL inhibitor and B-PAC-1, a procaspase activating compound with ibrutinib in chronic lymphocytic leukemia. Leuk Lymphoma 57(6):1-4, 2016. e-Pub 2016. PMID: 26440741.
Zaman S, Wang R, Gandhi V. Targeting executioner procaspase-3 with the procaspase-activating compound B-PAC-1 induces apoptosis in multiple myeloma cells. Exp Hematol 43(11):951-962.e3, 2015. e-Pub 2015. PMID: 26257207.
Balakrishnan K, Peluso M, Fu M, Rosin NY, Burger JA, Wierda WG, Keating MJ, Faia K, O'Brien S, Kutok JL, Gandhi V. The Phosphoinositide-3-Kinase (PI3K)-Delta and Gamma Inhibitor, IPI-145, Overcomes Signals from the PI3K/AKT/S6 Pathway and Promotes Apoptosis in CLL. Leukemia 29(9):1811-22, 2015. e-Pub 2015. PMID: 25917267.
Cervantes-Gomez F, Lamothe B, Woyach JA, Wierda WG, Keating MJ, Balakrishnan K, Gandhi V. Pharmacological and protein profiling suggest ABT-199 as optimal partner with ibrutinib in chronic lymphocytic leukemia. Clin Cancer Res 21(16):3705-15, 2015. e-Pub 2015. PMID: 25829398.
Wang J, Yin H, Panandikar A, Gandhi V, Sen S. Elevated cyclin A associated kinase activity promotes sensitivity of metastatic human cancer cells to DNA antimetabolite drug. Int J Oncol 47(2):782-90, 2015. e-Pub 2015. PMID: 26058363.
Zaman S, Shentu S, Yang J, He J, Orlowski RZ, Stellrecht CM, Gandhi V. Targeting the pro-survival protein MET with tivantinib (ARQ 197) inhibits growth of multiple myeloma cells. Neoplasia 17(3):289-300, 2015. e-Pub 2015. PMID: 25810013.
Patel V, Balakrishnan K, Keating MJ, Wierda WG, Gandhi V. Expression of executioner procaspases and their activation by a procaspase-activating compound in chronic lymphocytic leukemia cells. Blood 125(7):1126-36, 2015. e-Pub 2015. PMID: 25538042.
Lamothe B, Cervantes-Gomez F, Sivina M, Wierda WG, Keating MJ, Gandhi V. Proteasome inhibitor carfilzomib complements ibrutinib's action in chronic lymphocytic leukemia. Blood 125(2):407-10, 2015. e-Pub 2015. PMID: 25573971.
Kearney AY, Fan YH, Giri U, Saigal B, Gandhi V, Heymach JV, Zurita AJ. 8-Chloroadenosine Sensitivity in Renal Cell Carcinoma Is Associated with AMPK Activation and mTOR Pathway Inhibition. PLoS One 10(8):e0135962, 2015. e-Pub 2015. PMID: 26313261.
Balakrishnan K, Burger JA, Fu M, Doifode T, Wierda WG, Gandhi V. Regulation of Mcl-1 expression in Context to Bone Marrow Stromal Microenvironment in Chronic Lymphocytic Leukemia. Neoplasia 16(12):1036-46, 2014. e-Pub 2014. PMID: 25499217.
Yang Q, Modi P, Ramanathan S, Quéva C, Gandhi V. Idelalisib for the treatment of B-cell malignancies. Expert Opinion on Orphan Drugs 2(12):1-15, 2014. e-Pub 2014.
Chen LS, Keating MJ, Gandhi V. Blood collection methods affect cellular protein integrity: implications for clinical trial biomarkers and ZAP-70 in CLL. Blood 124(7):1192-5, 2014. e-Pub 2014. PMID: 25124785.
El-Mabhouh AA, Ayres ML, Shpall EJ, Baladandayuthapani V, Keating MJ, Wierda WG, Gandhi V. Evaluation of bendamustine in combination with fludarabine in primary chronic lymphocytic leukemia cells. Blood 123(24):3780-9, 2014. e-Pub 2014. PMID: 24747434.
Faderl S, Balakrishnan K, Thomas DA, Ravandi F, Borthakur G, Burger J, Ferrajoli A, Cortes J, O'Brien S, Kadia T, Feliu J, Plunkett W, Gandhi V, Kantarjian HM. Phase I and extension study of clofarabine plus cyclophosphamide in patients with relapsed/refractory acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk 14(3):231-8, 2014. e-Pub 2014. PMID: 24440659.
Chen W, Balakrishnan K, Kuang Y, Han Y, Fu M, Gandhi V, Peng X. Reactive oxygen species (ROS)-inducible DNA cross-linking agents and their effect on cancer cells and normal lymphocytes. J Med Chem 57(11):4498-510, 2014. e-Pub 2014. PMID: 24801734.
Patel V, Chen LS, Wierda WG, Balakrishnan K, Gandhi V. Impact of bone marrow stromal cells on Bcl-2 family members in chronic lymphocytic leukemia. Leuk Lymphoma 55(4):899-910, 2014. e-Pub 2014. PMID: 23837491.
Sandoval MR, Balakrishnan K, Luthra R, Keating M, Gandhi V. DNA repair initiation induces expression of ribonucleotide reductase in human chronic lymphocytic leukemia cells. Leuk Lymphoma 55(4):876-83, 2014. e-Pub 2014. PMID: 23772636.
Cao X, Mitra AK, Pounds S, Crews KR, Gandhi V, Plunkett W, Dolan ME, Hartford C, Raimondi S, Campana D, Downing J, Rubnitz JE, Ribeiro RC, Lamba JK. RRM1 and RRM2 pharmacogenetics: association with phenotypes in HapMap cell lines and acute myeloid leukemia patients. Pharmacogenomics 14(12):1449-66, 2013. e-Pub 2013. PMID: 24024897.
Balakrishnan K, Ravandi F, Bantia S, Franklin A, Gandhi V. Preclinical and clinical evaluation of forodesine in pediatric and adult B-cell acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk 13(4):458-66, 2013. e-Pub 2013. PMID: 23773454.
Balakrishnan K, Aggarwal S, Wierda W, Gandhi V. Bax and Bak are required for apogossypolone, a BH3-mimetic induced apoptosis in chronic lymphocytic leukemia cells. Leuk Lymphoma 54(5):1097-100, 2013. e-Pub 2013. PMID: 22866921.
Byers LA, Diao L, Wang J, Saintigny P, Girard L, Peyton M, Shen L, Fan Y, Giri U, Tumula PK, Nilsson MB, Gudikote J, Tran H, Cardnell RJ, Bearss DJ, Warner SL, Foulks JM, Kanner SB, Gandhi V, Krett N, Rosen ST, Kim ES, Herbst RS, Blumenschein GR, Lee JJ, Lippman SM, Ang KK, Mills GB, Hong WK, Weinstein JN, Wistuba II, Coombes KR, Minna JD, Heymach JV. An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin Cancer Res 19(1):279-90, 2013. e-Pub 2013. PMID: 23091115.
Phillip CJ, Zaman S, Shentu S, Balakrishnan K, Zhang J, Baladandayuthapani V, Taverna P, Redkar S, Wang M, Stellrecht CM, Gandhi V. Targeting MET kinase with the small-molecule inhibitor amuvatinib induces cytotoxicity in primary myeloma cells and cell lines. J Hematol Oncol 6:92, 2013. e-Pub 2013. PMID: 24326130.
Yang Q, Chen LS, Neelapu SS, Miranda RN, Medeiros LJ, Gandhi V. Transcription and translation are primary targets of pim kinase inhibitor, SGI-1776, in mantle cell lymphoma. Blood 120(17):3491-3500, 2012. e-Pub 2012. PMID: 22955922.
Pillai RN, Chen LS, Ayres ML, Nowak BJ, Thomas MW, Shpall EJ, Keating MJ, Gandhi V. Multifaceted actions of 8-amino-adenosine kill BCR-ABL positive cells. Leuk Lymphoma 53(10):2024-2032, 2012. e-Pub 2012. PMID: 22448923.
Jabbour E, Garcia-Manero G, Cortes J, Ravandi F, Plunkett W, Gandhi V, Faderl S, O'Brien S, Borthakur G, Kadia T, Burger J, Konopleva M, Brandt M, Huang X, Kantarjian H. Twice-daily fludarabine and cytarabine combination with or without gemtuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia. Clin Lymphoma Myeloma Leuk 12(4):244-251, 2012. e-Pub 2012. PMID: 22534616.
Ponader S, Chen SS, Buggy JJ, Balakrishnan K, Gandhi V, Wierda WG, Keating MJ, O'Brien S, Chiorazzi N, Burger JA. Bruton's tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood 119(5):1182-1189, 2012. e-Pub 2012. PMID: 22180443.
Faderl S, Garcia-Manero G, Jabbour E, Ravandi F, Borthakur G, Estrov Z, Gandhi V, Byrd AL, Kwari M, Cortes J, Kantarjian HM. A randomized study of 2 dose levels of intravenous clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome. Cancer 118(3):772-778, 2012. e-Pub 2012. PMID: 21751197.
McBrayer SK, Yarrington M, Qian J, Feng G, Shanmugam M, Gandhi V, Krett NL, Rosen ST. Integrative gene expression profiling reveals G6PD-mediated resistance to RNA-directed nucleoside analogues in B-cell neoplasms. PLoS One 7(7):e41455, 2012. e-Pub 2012. PMID: 22848499.
Kuang Y, Balakrishnan K, Gandhi V, Peng X. Hydrogen peroxide inducible DNA cross-linking agents: targeted anticancer prodrugs. J Am Chem Soc 133(48):19278-81, 2011. e-Pub 2011. PMID: 22035519.
Cervantes-Gomez F, Nimmanapalli R, Gandhi V. ATP analog enhances the actions of a heat shock protein 90 inhibitor in multiple myeloma cells. J Pharmacol Exp Ther 339(2):545-54, 2011. e-Pub 2011. PMID: 21821695.
Chen LS, Redkar S, Taverna P, Cortes JE, Gandhi V. Mechanisms of cytotoxicity to pim kinase inhibitor, SGI-1776, in acute myeloid leukemia. Blood 118(3):693-702, 2011. e-Pub 2011. PMID: 21628411.
Mitra AK, Crews KR, Pounds S, Cao X, Feldberg T, Ghodke Y, Gandhi, V, Plunkett W, Dolar EM, Hartford C, Raimondi S, Campana D, Downing J, Rubnitz JE, Ribeiro RC, Lamba JK. Genetic variants in NT5C2 are associated with its expression and cytarabine sensitivity in HapMap cell lines and in AML patients. J Pharmacol Exp Therap 12(1):327-339, 2011. e-Pub 2011. PMID: 21712425.
Lamba J, Crews KR, Pounds SB, Cao X, Gandhi V, Plunkett W, Razzouk BI, Lamba V, Baker SD, Raimondi SC, Campana D, C-H P, Downing JR, Rubnitz JE, Ribeiro RC. Identification of predictive markers of cytarabine response in acute myeloid leukemia by integrative analysis of gene-expression profiles with multiple phenotypes. Pharmacogenomics 12(3):327-339, 2011. e-Pub 2011. PMID: 21449673.
Zhang H, Gogada R, Yadav N, Lella RK, Badeaux M, Ayres M, Gandhi V, Tang DG, Chandra D. Defective molecular timer in the absence of nucleotides leads to inefficient caspase activation. PLoS One 6(1):e16379, 2011. e-Pub 2011. PMID: 21297999.
Dennison JB, Shanmugam M, Ayres ML, Qian J, Krett NL, Medeiros LJ, Neelapu SS, Rosen ST, Gandhi V. 8-Aminoadenosine inhibits Akt/mTOR and Erk signaling in mantle cell lymphoma. Blood 116(25):5622-30, 2010. e-Pub 2010. PMID: 20844237.
Balakrishnan K, Verma D, O'Brien S, Kilpatrick JM, Chen Y, Tyler BF, Bickel S, Bantia S, Keating MJ, Kantarjian H, Gandhi V, Ravandi F. Phase 2 and pharmacodynamic study of oral forodesine in patients with advanced, fludarabine-treated chronic lymphocytic leukemia. Blood 116(6):886-892, 2010. e-Pub 2010. PMID: 20427701.
Balakrishnan K, Burger JA, Quiroga MP, Henneberg M, Ayres ML, Wierda WG, Gandhi V. Influence of bone marrow stromal microenvironment on forodesine-induced responses in CLL primary cells. Blood 116(7):1083-1091, 2010. e-Pub 2010. PMID: 20442367.
Chen R, Chubb S, Cheng T, Hawtin RE, Gandhi V, Plunkett W. Responses in mantle cell lymphoma cells to SNS-032 depend on the biological context of each cell line. Cancer Res 70(16):6587-6597, 2010. e-Pub 2010. PMID: 20663900.
Faderl S, Garcia-Manero G, Estrov Z, Ravandi F, Borthakur G, Cortes JE, O'Brien S, Gandhi V, Plunkett W, Byrd A, Kwari M, Kantarjian HM. Oral clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome. J Clin Oncol 28(16):2755-2760, 2010. e-Pub 2010. PMID: 20421540.
Stellrecht CM, Ayres M, Arya R, Gandhi V. A unique RNA-directed nucleoside analog is cytotoxic to breast cancer cells and depletes cyclin E levels. Breast Cancer Res Treat 121(2):355-364, 2010. e-Pub 2010. PMID: 19641990.
Lyu MA, Rai D, Ahn KS, Sung B, Cheung LH, Marks JW, Aggarwal BB, Aguiar RC, Gandhi V, Rosenblum MG. The rGel/BLyS fusion toxin inhibits diffuse large B-cell lymphoma growth in vitro and in vivo. Neoplasia 12(5):366-375, 2010. e-Pub 2010. PMID: 20454508.
Chen LS, Du-Cuny L, Vethantham V, Hawke DH, Manley JL, Zhang S, Gandhi V. Chain termination and inhibition of mammalian poly(A) polymerase by modified ATP analogues. Biochem Pharmacol 79(5):669-677, 2010. e-Pub 2010. PMID: 19814999.
Dennison JB, Ayres ML, Kaluarachchi K, Plunkett W, Gandhi V. Intracellular succinylation of 8-chloroadenosine and its effect on fumarate levels. J Biol Chem 285(11):8022-8030, 2010. e-Pub 2010. PMID: 20064937.
Frey JA, Gandhi V. 8-Amino-adenosine inhibits multiple mechanisms of transcription. Mol Cancer Ther 9(1):239-245, 2010. e-Pub 2010. PMID: 20053765.
Rubnitz JE, Crews KR, Pounds S, Yang S, Campana D, Gandhi V, Raimondi SC, Downing JR, Bi R, C-H P, Ribeiro RC. Combination of cladribine and cytarabine is effective for childhood acute myeloid leukemia: Results of the St. Jude AML97 trial. Leukemia 23(8):1410-1416, 2009. e-Pub 2009. PMID: 19242495.
Balakrishnan K, Burger JA, Wierda WG, Gandhi V. AT-101 induces apoptosis in CLL B cells and overcomes stromal cell-mediated Mcl-1 induction and drug resistance. Blood 113(1):149-153, 2009. e-Pub 2009. PMID: 18836097.
Chen LS, Redkar S, Bearss D, Wierda WG, Gandhi V. Pim kinase inhibitor, SGI-1776, induces apoptosis in chronic lymphocytic leukemia cells. Blood 114(19):4150-4157, 2009. e-Pub 2009. PMID: 19734450.
Gandhi V, Burger JA. Bendamustine in B cell malignancies: the new, 46-year old kid on the block. Clin Cancer Res 15(24):7456-7461, 2009. e-Pub 2009. PMID: 19996200.
Chen LS, Nowak BJ, Ayres ML, Krett NL, Rosen ST, Zhang S, Gandhi V. Inhibition of ATP synthase by chlorinated adenosine analogue. Biochem Pharmacol 78(6):583-591, 2009. e-Pub 2009. PMID: 19477165.
Quiroga MP, Balakrishnan K, Kurtova AV, Sivina M, Keating MJ, Wierda WG, Gandhi V, Burger JA. B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406. Blood 114(5):1029-1037, 2009. e-Pub 2009. PMID: 19491390.
Kurtova AV, Balakrishnan K, Chen R, Ding W, Schnabl S, Quiroga MP, Sivina M, Wierda WG, Estrov Z, Keating MJ, Shehata M, Jäger U, Gandhi V, Kay NE, Plunkett W, Burger JA. Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance. Blood 114(20):4441-4450, 2009. e-Pub 2009. PMID: 19762485.
Shanmugam M, McBrayer SK, Qian J, Raikoff K, Avram MJ, Singhal S, Gandhi V, Schumacker PT, Krett NL, Rosen ST. Targeting glucose consumption and autophagy in myeloma with the novel nucleoside analogue, 8-amino-adenosine. J Biol Chem 284(39):26816-26830, 2009. e-Pub 2009. PMID: 19648108.
Cervantes-Gomez F, Nimmanapalli R, Gandhi V. Transcription inhibition of heat shock proteins: A strategy for combination of 17-allylamino-17-demethoxy-geldanamycin and actinomycin D. Cancer Res 69(9):3947-3954, 2009. e-Pub 2009. PMID: 19383903.
Dennison JB, Balakrishnan K, Gandhi V. Preclinical activity of 8-chloroadenosine with mantle cell lymphoma: roles of energy depletion and inhibition of DNA and RNA synthesis. Br J Haematol 147(3):297-307, 2009. e-Pub 2009. PMID: 19709085.
Guo Y, Köck K, Ritter CA, Chen ZS, Grube M, Jedlitschky G, Illmer T, Ayres M, Beck JF, Siegmund W, Ehninger G, Gandhi V, Kroemer HK, Kruh GD, Schaich M. Expression of ABCC-type nucleotide exporters in blasts of adult acute myeloid leukemia: relation to long-term survival. Clin Cancer Res 15(5):1762-1769, 2009. e-Pub 2009. PMID: 19240178.
Chen R, Wierda WG, Chubb S, Hawtin RE, Fox JA, Keating MJ, Gandhi V, Plunkett W. Mechanism of action of SNS-032, a novel cyclin dependent kinase inhibitor, in chronic lymphocytic leukemia. Blood 113(19):4637-4645, 2009. e-Pub 2009. PMID: 19234140.
Phillip CJ, Stellrecht CM, Nimmanapalli R, Gandhi V. Targeting MET transcription as a therapeutic strategy in multiple myeloma. Cancer Chemother Pharmacol 63(4):587-597, 2009. e-Pub 2009. PMID: 18509644.
Pounds S, Cheng C, Cao X, Crews KR, Plunkett W, Gandhi V, Rubnitz J, Ribeiro RC, Downing JR, Lamba J. PROMISE: a tool to identify genomic features with a specific biologically interesting pattern of associations with multiple endpoint variables. Bioinformatics 25(16):2013-2019, 2009. e-Pub 2009. PMID: 19528086.
Sánchez-Vega B, Gandhi V. Glucocorticoid resistance in a multiple myeloma cell line is regulated by a transcription elongation block in the glucocorticoid receptor gene (NR3C1). Br J Haematol 144(6):856-864, 2009. e-Pub 2009. PMID: 19133980.
Gandhi V, Tam C, O'Brien S, Jewell RC, Rodriguez CO, Lerner S, Plunkett W, Keating MJ. Phase I trial of nelarabine in indolent leukemias. J Clin Oncol 26(7):1098-1105, 2008. e-Pub 2008. PMID: 18309944.
Chen L, Stellrecht C, Gandhi V. A polyadenylation inhibitor, cordycepin, decreases MET transcript levels and induces cell death in multiple myeloma cells. Brit J Hemat 140(6):682-691, 2008. e-Pub 2008. PMID: 18205859.
Balakrishnan K, Wierda WG, Keating MJ, Gandhi V. Gossypol, a BH3 mimetic, induces apoptosis in chronic lymphocytic leukemia cells. Blood 112(5):1971-1980, 2008. e-Pub 2008. PMID: 18566329.
Borthakur G, Kantarjian H, Wang X, Plunkett WK, Gandhi VV, Faderl S, Garcia-Manero G, Ravandi F, Pierce S, Estey EH. Treatment of core-binding-factor in acute myelogenous leukemia with fludarabine, cytarabine, and granulocyte colony-stimulating factor results in improved event-free survival. Cancer 113(11):3181-3185, 2008. e-Pub 2008. PMID: 18932257.
Nimmanapalli R, Gerbino E, Dalton WS, Gandhi V, Alsina M. HSP70 inhibition reverses cell adhesion mediated and acquired drug resistance in multiple myeloma. Br J Haematol 142:551-561, 2008. e-Pub 2008. PMID: 18503584.
Chen LS, Plunkett W, Gandhi V. Polyadenylation inhibition by the triphosphates of deoxyadenosine analogues. Leuk Res 32(10):1573-1581, 2008. e-Pub 2008. PMID: 18433867.
Chen LS, Stellrecht CM, Gandhi V. RNA-directed agent, cordycepin, induces cell death in multiple myeloma cells. Br J Haematol 140(6):682-691, 2008. e-Pub 2008. PMID: 18205859.
Stellrecht CM, Phillip CJ, Cervantes-Gomez F, Gandhi V. Multiple myeloma cell killing by depletion of the MET receptor tyrosine kinase. Cancer Res 67(20):9913-9920, 2007. e-Pub 2007. PMID: 17942923.
Karp JE, Ricklis RM, Balakrishnan K, Briel J, Greer J, Gore SD, Smith BD, McDevitt MA, Carraway H, Levis MJ, Gandhi V. A phase 1 clinical-laboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemias. Blood 110(6):1762-1769, 2007. e-Pub 2007. PMID: 17562873.
Nimmanapalli R, Lyu MA, Du M, Keating MJ, Rosenblum M, Gandhi V. The growth factor fusion construct containing B-lymphocyte stimulator (BLyS) and the toxin rGel induces apoptosis specifically in BAFF-R positive CLL cells. Blood 109(6):2557-2564, 2007. e-Pub 2007. PMID: 17119117.
Flanagan SA, Gandhi V, Meckling KA. Guanosine acts intracellularly to initiate apoptosis in NB4 cells: A role for nucleoside transport. Leuk Lymphoma 48(9):1816-1827, 2007. e-Pub 2007. PMID: 17786719.
Lamba JK, Crews C, Pounds S, Schuetz EG, Gresham J, Gandhi V, Plunkett W, Rubnitz J, Ribeiro R. Pharmacogenetics of deoxycytidine kinase: Identification and characterization of novel genetic variants. J Pharmacol Exp Therap 323(3):935-945, 2007. e-Pub 2007. PMID: 17855478.
Chandra D, Bratton SB, Person MD, Tian Y, Martin AG, Ayres M, Fearnhead HO, Gandhi V, Tang DG. Intracellular nucleotides act as critical prosurvival factors by binding to cytochrome C and inhibiting apoptosome. Cell 125(7):1333-46, 2006. e-Pub 2006. PMID: 16814719.
Sampath D, Cortes J, Estrov Z, Du M, Shi Z, Andreeff M, Gandhi V, Plunkett W. Pharmacodynamics of cytarabine alone and in combination with 7-hydroxystaurosporine (UCN-01) in AML blasts in vitro and during a clinical trial. Blood 107(6):2517-24, 2006. e-Pub 2006. PMID: 16293603.
Balakrishnan K, Nimmanapalli R, Ravandi F, Keating MJ, Gandhi V. Forodesine, an inhibitor of purine nucleoside phosphorylase, induces apoptosis in chronic lymphocytic leukemia cells. Blood 108:2392-2398, 2006. e-Pub 2006. PMID: 16778146.
Chen R, Gandhi V, Plunkett W. A sequential blockade strategy for the design of combination therapies to overcome oncogene addiction in chronic myelogenous leukemia. Cancer Res 66:10959-10966, 2006. e-Pub 2006. PMID: 17108134.
Sanchez-Vega B, Krett N, Rosen ST, Gandhi V. Glucocorticoid receptor transcriptional isoforms and resistance in multiple myeloma cells. Mol Cancer Therapeutics 5:3062-3070, 2006. e-Pub 2006. PMID: 17172408.
Gandhi V, Plunkett W, Bonate PL, Du M, Nowak B, Lerner S, Keating MJ. Clinical and pharmacokinetic study of clofarabine in chronic lymphocytic leukemia: strategy for treatment. Clin Cancer Res 12:4011-4017, 2006. e-Pub 2006. PMID: 16818700.
Gandhi V, Kilpatrick JM, Plunkett W, Ayres M, Harman L, Du M, Bantia S, Davisson J, Wierda WG, Faderl S, Kantarjian H, Thomas D. A proof-of-principle pharmacokinetic, pharmacodynamic, and clinical study with purine nucleoside phosphorylase inhibitor immucillin-H (BCX-1777, forodesine). Blood 106(13):4253-60, 2005. e-Pub 2005. PMID: 16131572.
Chen R, Keating MJ, Gandhi V, Plunkett W. Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death. Blood 106(7):2513-9, 2005. e-Pub 2005. PMID: 15972445.
Balakrishnan K, Wierda WG, Keating MJ, Gandhi V. Mechanisms of cell death of chronic lymphocytic leukemia lymphocytes by RNA-directed agent, 8-NH2-adenosine. Clin Cancer Res 11(18):6745-52, 2005. e-Pub 2005. PMID: 16166456.
Jabbour E, Verstovsek S, Giles F, Gandhi V, Cortes J, O'Brien S, Plunkett W, Garcia-Manero G, Jackson CE, Kantarjian H, Andreeff M. 2-Chlorodeoxyadenosine and cytarabine combination therapy for idiopathic hypereosinophilic syndrome. Cancer 104(3):541-6, 2005. e-Pub 2005. PMID: 15977212.
Ghias K, Ma C, Gandhi V, Platanias LC, Krett NL, Rosen ST. 8-Amino-adenosine induces loss of phosphorylation of p38 mitogen-activated protein kinase, extracellular signal-regulated kinase 1/2, and Akt kinase: role in induction of apoptosis in multiple myeloma. Mol Cancer Ther 4:569-577, 2005. e-Pub 2005. PMID: 15827330.
Chen R, Keating MJ, Gandhi V, Plunkett W. Flavopiridol-induced apoptosis in chronic lymphocytic leukemia cells through the transcriptional inhibition of anti-apoptotic proteins. Blood 106:2513-2519, 2005. e-Pub 2005.
Cooper T, Ayres M, Nowak B, Gandhi V. Biochemical modulation of cytarabine triphosphate by clofarabine. Cancer Chemother Pharmacol 55:361-368, 2005. e-Pub 2005. PMID: 15723262.
Balakrishnan K, Stellrecht CM, Genini D, Ayres M, Wierda WG, Keating MJ, Leoni LM, Gandhi V. Cell death of bioenergetically compromised and transcriptionally challenged CLL lymphocytes by chlorinated ATP. Blood 105:4455-4462, 2005. e-Pub 2005. PMID: 15718423.
Faderl S, Gandhi V, O'Brien S, Bonate P, Cortes J, Estey E, Beran M, Wierda W, Garcia-Manero G, Ferrajoli A, Estrov Z, Giles FJ, Du M, Kwari M, Keating M, Plunkett W, Kantarjian H. Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias. Blood 105:940-947, 2005. e-Pub 2005. PMID: 15486072.
Kurtzberg J, Ernst TJ, Keating MJ, Gandhi V, Hodge JP, Kisor DF, Lager JJ, Stephens C, Levin J, Krenitsky T, Elion G, Mitchell BS. Phase I study of 506U78 administered on a consecutive 5-day schedule in children and adults with refractory hematologic malignancies. J Clin Oncol 23:3396-3403, 2005. e-Pub 2005. PMID: 15908652.
Krett NL, Davies KM, Ayres M, Ma C, Nabhan C, Gandhi V, Rosen ST. 8-amino-adenosine is a potential therapeutic agent for multiple myeloma. Mol Cancer Ther 3(11):1411-20, 2004. e-Pub 2004. PMID: 15542780.
Krett NL, Ayres M, Nabhan C, Ma C, Nowak B, Nawrocki S, Rosen ST, Gandhi V. In vitro assessment of nucleoside analogs in multiple myeloma. Cancer Chemother Pharmacol 54(2):113-21, 2004. e-Pub 2004. PMID: 15133625.
Bonate PL, Craig A, Gaynon P, Gandhi V, Jeha S, Kadota R, Lam GN, Plunkett W, Razzouk B, Rytting M, Steinherz P, Weitman S. Population pharmacokinetics of clofarabine, a second-generation nucleoside analog, in pediatric patients with acute leukemia. J Clin Pharmacol 44:1309-1322, 2004. e-Pub 2004. PMID: 15496649.
Jeha S, Gandhi V, Chan KW, McDonald L, Ramirez I, Madden R, Rytting M, Brandt M, Keating M, Plunkett W, Kantarjian H. Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia. Blood 103:784-789, 2004. e-Pub 2004. PMID: 14551141.
Kantarjian HM, Gandhi V, Kozuch P, Faderl S, Giles F, Cortes J, O'Brien S, Ibrahim N, Khuri F, Du M, Rios MB, Jeha S, McLaughlin P, Plunkett W, Keating M. Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers. J Clin Oncol 21:1167-1173, 2003. e-Pub 2003. PMID: 12637486.
Kantarjian H, Gandhi V, Cortes J, Verstovsek S, Du M, Garcia-Manero G, Giles F, Faderl S, O'Brien S, Jeha S, Davis J, Shaked Z, Craig A, Keating M, Plunkett W, Freireich EJ. Phase II clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood 102:2379-2386, 2003. e-Pub 2003. PMID: 12791647.
Gandhi V, Kantarjian H, Faderl S, Bonate P, Du M, Ayres M, Rios MB, Keating MJ, Plunkett W. Pharmacokinetics and pharmacodynamics of plasma clofarabine and cellular clofarabine triphosphate in patients with acute leukemias. Clin Cancer Res 9:6335-6342, 2003. e-Pub 2003. PMID: 14695132.
Flanagan SA, Gandhi V, Secrist JA, Meckling KA. The novel nucleoside transport system exhibited by NB4 cells, csg, transports deoxyguanosine analogues, including ara-G. Biochem Pharmacol 66:733-737, 2003. e-Pub 2003. PMID: 12948853.
Sharma G, Gupta A, Wang H, Scherthan H, Dhar S, Gandhi V, Iliakis G, Shay JW, Young CS, Pandita TK. TERT expression reduces spontaneous chromosome damage and enhances DNA repair. Oncogene 22:131-146, 2003. e-Pub 2003. PMID: 12527915.
Giles FJ, Fracasso PM, Kantarjian HM, Cortes JE, Brown RA, Verstovsek S, Alvarado Y, Thomas DA, Faderl S, Garcia-Manero G, Wright LP, Samson T, Cahill A, Lambert P, Plunkett W, Sznol M, DiPersio JF, Gandhi V. Phase I and pharmacodynamic study of Triapine, a novel ribonucleotide reductase inhibitor, in patients with advanced leukemia. Leukemia Res 27:1077-1083, 2003. e-Pub 2003. PMID: 12921943.
Rodriguez CO Jr, Stellrecht CM, Gandhi V. Mechanisms for T-cell selective cytotoxicity of arabinosylguanine (Accompanied with an editorial). Blood 102:1842-1848, 2003. e-Pub 2003. PMID: 12750168.
Stellrecht CM, Rodriguez CO Jr, Ayres M, Gandhi V. RNA-directed actions of 8-chloro-adenosine in multiple myeloma cells. Cancer Res 63:7968-7974, 2003. e-Pub 2003. PMID: 14633728.
Nabhan C, Gajria D, Krett NL, Gandhi V, Ghias K, Rosen ST. Caspase activation is required for gemcitabine activity in multiple myeloma cell lines. Mol Cancer Ther 1(13):1221-7, 2002. e-Pub 2002. PMID: 12479703.
Crews KR, Gandhi V, Srivastava DK, Razzouk BI, Tong X, Behm FG, Plunkett W, Raimondi SC, Pui CH, Rubnitz JE, Stewart CF, Ribeiro RC. Interim comparison of a continuous infusion versus a short daily infusion of cytarabine given in combination with cladribine for pediatric acute myeloid leukemia. J Clin Oncol 20(20):4217-24, 2002. e-Pub 2002. PMID: 12377965.
Gandhi V, Chen W, Ayres M, Rhie JK, Madden TL, Newman RA. Plasma and cellular pharmacology of 8-chloro-adenosine in mice and rats. Cancer Chemother Pharmacol 50:85-94, 2002. e-Pub 2002. PMID: 12172971.
Zhou Y, Achanta G, Pelicano H, Gandhi V, Plunkett W, Huang P. Action of (E)-2'-deoxy-2'-(fluoromethylene)cytidine on DNA metabolism: incorporation, excision, and cellular response. Mol Pharmacol 61:222-229, 2002. e-Pub 2002. PMID: 11752224.
Rodriguez CO Jr, Mitchell BS, Ayres M, Eriksson S, Gandhi V. Arabinosylguanine is phosphorylated by both cytoplasmic deoxycytidine kinase and mitochondrial deoxyguanosine kinase. Cancer Res 62:3100-3105, 2002. e-Pub 2002. PMID: 12036920.
Lin-Lee YC, Nakamura S, Gandhi V, Curley SA, Stuber D, Burkot TR, Kuo MT. Prolonged stability and sustained prodrug cell killing activity using receptor-mediated delivery of malarial circumsporozoite-cytosine deaminase fusion protein into liver cancer cells. Mol Cancer Therapeutics 1:461-467, 2002. e-Pub 2002. PMID: 12479264.
Stellrecht CM, Gandhi V. Concurrent isolation of ribosomal, messenger, and low molecular weight RNA. Biotechniques 33:1122-1124, 2002. e-Pub 2002. PMID: 12449393.
Gandhi V, Plunkett W, Du M, Ayres M, Estey EH. Prolonged infusion of gemcitabine: clinical and pharmacodynamic studies during a phase I trial in relapsed acute myelogenous leukemia. J Clin Oncol 20:665-673, 2002. e-Pub 2002. PMID: 11821446.
Gandhi V, Plunkett W, Weller S, Du M, Ayres M, Jr RC, Ramakrishna P, Rosner GL, Hodge JP, O'Brien S, Keating MJ. Evaluation of the combination of nelarabine and fludarabine in leukemias: clinical response, pharmacokinetics, and pharmacodynamics in leukemia cells. J Clin Oncol 19:2142-2152, 2001. e-Pub 2001. PMID: 11304766.
Gandhi V, Ayres M, Halgren RG, Krett NL, Newman RA, Rosen ST. Metabolism and action of 8-chloro-cAMP and 8-Chloro-adenosine in multiple myeloma. Cancer Res 61:5474-5479, 2001. e-Pub 2001. PMID: 11454694.
Patel SR, Gandhi V, Jenkins J, Papadopolous N, Burgess MA, Plager C, Plunkett W, Benjamin RS. Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation. J Clin Oncol 19:3483-3489, 2001. e-Pub 2001. PMID: 11481354.
Kisor DF, Plunkett W, Kurtzberg J, Mitchell B, Hodge JP, Ernst T, Keating MJ, Gandhi V. The pharmacokinetics of 506U78 and ara-G in pediatric and adult patients during a Phase I study of 506U78 for the treatment of refractory hematologic malignancies. J Clin Oncol 18(5):995-1003, 2000. e-Pub 2000. PMID: 10694549.
Rodriguez CO Jr, Plunkett W, Paff MT, Du M, Nowak B, Ramakrishna P, Keating MJ, Gandhi V. High-performance liquid chromatography method for the determination and quantitation of arabinosylguanine triphosphate and fludarabine triphosphate in human cells. J Chromatogr B Biomed Sci Appl 745:421-430, 2000. e-Pub 2000. PMID: 11043760.
Rodriguez CO Jr, Gandhi V. Arabinosylguanine-induced apoptosis of T-lymphoblastic cells: incorporation into DNA is a necessary step. Cancer Res 59:4937-4943, 1999. e-Pub 1999. PMID: 10519407.
Dumontet C, Fabianowska-Majewska K, Mantincic D, Callet Bauchu E, Tigaud I, Gandhi V, Lepoivre M, Peters GJ, Rolland MO, Wyczechowska D, Fang X, Gazzo S, Voorn DA, Vanier-Viornery A, MacKey J. Common resistance mechanisms to deoxynucleoside analogues in variants of the human erythroleukaemic line K562. Br J Haematol 106:78-85, 1999. e-Pub 1999. PMID: 10444166.
Giles FJ, O'Brien SM, Santini V, Gandhi V, Plunkett W, Seymour JF, Robertson LE, Kantarjian HM, Keating MJ. Sequential cis-platinum and fludarabine with or without arabinosyl cytosine in patients failing prior fludarabine therapy for chronic lymphocytic leukemia: a phase II study. Leuk Lymphoma 36:57-65, 1999. e-Pub 1999. PMID: 10613450.
Gandhi V, Plunkett W, Kantarjian H, Talpaz M, Robertson LE, O'Brien S. Cellular pharmacodynamics and plasma pharmacokinetics of parenterally infused hydroxyurea during a phase I clinical trial in chronic myelogenous leukemia. J Clin Oncol 16:2321-2331, 1998. e-Pub 1998. PMID: 9667246.
Gandhi V, Plunkett W, Jr RC, Nowak BJ, Du M, Ayres M, Kisor DF, Mitchell BS, Kurtzberg J, Keating MJ. Compound GW506U78 in refractory hematologic malignancies: relationship between cellular pharmacokinetics and clinical response. J Clin Oncol 16:3607-3615, 1998. e-Pub 1998. PMID: 9817282.
Gandhi V, Xu YZ, Estey E. Accumulation of arabinosyluracil 5'-triphosphate during arabinosylcytosine therapy in circulating blasts of patients with acute myelogenous leukemia. Clin Cancer Res 4:1719-1726, 1998. e-Pub 1998. PMID: 9676847.
Rodriguez CO Jr, Legha JK, Estey E, Keating MJ, Gandhi V. Pharmacological and biochemical strategies to increase the accumulation of arabinofuranosylguanine triphosphate in primary human leukemia cells. Clin Cancer Res 3(11):2107-13, 1997. e-Pub 1997. PMID: 9815603.
Gandhi V, Estey E, Du M, Keating MJ, Plunkett W. Minimum dose of fludarabine for the maximal modulation of 1-beta-D-arabinofuranosylcytosine triphosphate in human leukemia blasts during therapy. Clin Cancer Res 3:1539-1545, 1997. e-Pub 1997. PMID: 9815841.
Gandhi V, Huang P, Chapman AJ, Chen F, Plunkett W. Incorporation of fludarabine and 1-beta-D-arabinofuranosylcytosine 5'-triphosphates by DNA polymerase alpha: affinity, interaction, and consequences. Clin Cancer Res 3:1347-1355, 1997. e-Pub 1997. PMID: 9815818.
Gandhi V, Legha J, Chen F, Hertel LW, Plunkett W. Excision of 2',2'-difluorodeoxycytidine (gemcitabine) monophosphate residues from DNA. Cancer Res 56:4453-4459, 1996. e-Pub 1996. PMID: 8813140.
Kornblau SM, Gandhi V, Andreeff HM, Beran M, Kantarjian HM, Koller CA, O'Brien S, Plunkett W, Estey E. Clinical and laboratory studies of 2-chlorodeoxyadenosine +/- cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults. Leukemia 10:1563-1569, 1996. e-Pub 1996. PMID: 8847890.
Seymour JF, Huang P, Plunkett W, Gandhi V. Influence of fludarabine on pharmacokinetics and pharmacodynamics of cytarabine: implications for a continuous infusion schedule. Clin Cancer Res 2:653-658, 1996. e-Pub 1996. PMID: 9816215.
Loughlin S, Gandhi V, Plunkett W, Zwelling LA. The effect of 9-beta-D-arabinofuranosyl-2-fluoroadenine and 1-beta-D-arabinofuranosylcytosine on the cell cycle phase distribution, topoisomerase II level, mitoxantrone cytotoxicity, and DNA strand break production in K562 human leukemia cells. Cancer Chemother Pharmacol 38:261-268, 1996. e-Pub 1996. PMID: 8646801.
Gandhi V, Estey E, Keating MJ, Chucrallah A, Plunkett W. Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia: pharmacokinetic, pharmacodynamic, and molecular interactions. Blood 87:256-264, 1996. e-Pub 1996. PMID: 8547650.
Gandhi V, Mineishi S, Huang P, Chapman AJ, Yang Y, Chen F, Nowak B, Chubb S, Hertel LW, Plunkett W. Cytotoxicity, metabolism, and mechanisms of action of 2',2'-difluorodeoxyguanosine in Chinese hamster ovary cells. Cancer Res 55:1517-1524, 1995. e-Pub 1995. PMID: 7533664.
Gandhi V, Estey E, Du M, Nowak B, Keating MJ, Plunkett W. Effect of granulocyte colony stimulating factor on the cellular metabolism of cytarabine and fludarabine during therapy of acute myelogenous leukemia. Clin Cancer Res 1:169-178, 1995. e-Pub 1995. PMID: 9815970.
Gandhi V, Robertson LE, Keating MJ, Plunkett W. Combination of fludarabine and arabinosylcytosine for treatment of chronic lymphocytic leukemia: clinical efficacy and modulation of arabinosylcytosine pharmacology. Cancer Chemother Pharmacol 34(1):30-36, 1994. e-Pub 1994. PMID: 8174200.
Gandhi V, Du M, Kantarjian HM, Plunkett W. Effect of granulocyte-macrophage colony-stimulating factor on the metabolism of arabinosylcytosine triphosphate in blasts during therapy of patients with chronic myelogenous leukemia. Leukemia 8:1463-1468, 1994. e-Pub 1994. PMID: 8090026.
Gandhi V, Estey E, Keating MJ, Plunkett W. Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy. J Clin Oncol 11(1):116-24, 1993. e-Pub 1993. PMID: 8418222.
Gandhi V, Kemena A, Keating MJ, Plunkett W. Cellular pharmacology of fludarabine triphosphate in chronic lymphocytic leukemia cells during fludarabine therapy. Leuk Lymphoma 10(1-2):49-56, 1993. e-Pub 1993. PMID: 8374523.
Estey E, Plunkett W, Gandhi V, Rios MB, Kantarjian H, Keating MJ. Fludarabine and arabinosylcytosine therapy of refractory and relapsed acute myelogenous leukemia. Leuk Lymphoma 4(4-5):343-350, 1993. e-Pub 1993. PMID: 8394169.
Suki S, Kantarjian H, Gandhi V, Estey E, O'Brien S, Beran M, Rios MB, Plunkett W, Keating M. Fludarabine and cytosine arabinoside in the treatment of refractory or relapsed acute lymphocytic leukemia. Cancer 72(7):2155-2160, 1993. e-Pub 1993. PMID: 8374873.
Gandhi V, Plunkett W. Cell cycle-specific metabolism of arabinosyl nucleosides in K562 human leukemia cells. Cancer Chemother Pharmacol 31(1):11-17, 1992. e-Pub 1992. PMID: 1458554.
Gandhi V, Kemena A, Keating MJ, Plunkett W. Fludarabine infusion potentiates arabinosylcytosine metabolism in lymphocytes of patients with chronic lymphocytic leukemia. Cancer Res 52(4):897-903, 1992. e-Pub 1992. PMID: 1737352.
Kemena A, Gandhi V, Shewach DS, Keating M, Plunkett W. Inhibition of fludarabine metabolism by arabinosylcytosine during therapy. Cancer Chemother Pharmacol 31(3):193-199, 1992. e-Pub 1992. PMID: 1464155.
Gandhi V, Plunkett W. Modulatory activity of 2',2'-difluorodeoxycytidine on the phosphorylation and cytotoxicity of arabinosyl nucleosides. Cancer Res 50(12):3675-3680, 1990. e-Pub 1990. PMID: 2340517.
Sehgal CB, Gandhi V. Qualification of nucleic acids and some metabolites during embryo development in Vigna mungo (L.) hepper and Vigna radiata (L.) wilczek. Acta Bot Indica 18:199-203, 1990. e-Pub 1990.
Sehgal C, Gandhi V. Histological and histochemical studies on the cotyledons of some legumes. III. Nucleic acids during seed development. Acta Bot Indica 17:94-100, 1989. e-Pub 1989.
Gandhi V, Nowak B, Keating MJ, Plunkett W. Modulation of arabinosylcytosine metabolism by arabinosyl-2-fluoroadenine in lymphocytes from patients with chronic lymphocytic leukemia: implications for combination therapy. Blood 74(6):2070-2075, 1989. e-Pub 1989. PMID: 2478221.
Gandhi V, Plunkett W. Interaction of arabinosyl nucleotides in K562 human leukemia cells. Biochem Pharmacol 38(20):3551-3558, 1989. e-Pub 1989. PMID: 2479383.
Gandhi V, Plunkett W. Modulation of arabinosylnucleoside metabolism by arabinosylnucleotides in human leukemia cells. Cancer Res 48(2):329-334, 1988. e-Pub 1988. PMID: 3335008.
Gandhi V, Danhauser L, Plunkett W. Separation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate and 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-triphosphate in human leukemia cells by high-performance liquid chromatography. J Chromatography 413:293-299, 1987. e-Pub 1987. PMID: 3558682.
Sehgal CB, Gandhi V, Varma B. Histological and histochemical studies on the cotyledons of some legumes. II. Reserve metabolites during seed development. Cytologia 52:847-858, 1987. e-Pub 1987.
Danhauser L, Plunkett W, Liliemark J, Gandhi V, Iacoboni S, Keating M. Comparison between the plasma and intracellular pharmacology of 1-beta-D-arabinofuranosylcytosine and 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate in patients with relapsed leukemia. Leukemia 1(9):638-643, 1987. e-Pub 1987. PMID: 3478543.
Sehgal CB, Gandhi V. Histological and histochemical studies on the cotyledons of some legumes. I Changes during seed development. Phytomorphology 37:9-16, 1987. e-Pub 1987.
Sehgal CB, Gandhi V. Histology and histochemistry of pericarp of grain legumes: Cajanus cajan, Vigna mungo and Vigna radiata. Cytologia 51:333-339, 1986. e-Pub 1986.
Sehgal CB, Gandhi V. Studies on the endosperm of Cajanus cajan with special emphasis on the function. Phytomorphology 35:201-206, 1985. e-Pub 1985.
Sharp ZD, Gandhi V, Procunier JD. X chromosome nucleolus organizer mutants which alter major type I repeat multiplicity in Drosophila melanogaster. Mol Gen Genet 190:438-443, 1983. e-Pub 1983. PMID: 6308398.
Gandhi V. Tissue culture of chinese tallow - an euphorbiaceous tree. Current Sci 52:365-367, 1983. e-Pub 1983.
Venketeswaran S, Gandhi V. Mass propagation and genetic improvement of forest trees for biomass production by tissue culture. Biomass 2:5-15, 1982. e-Pub 1982.
Gandhi V, Sharp ZD, Procunier JD. Analysis of Y chromosome nucleolar organizer mutants in Drosophila melanogaster. Biochem Biophys Res Comm 104:778-784, 1982. e-Pub 1982. PMID: 6803790.
Sharp ZD, Gandhi V, Kalumuck K, Procunier JD. A rapid method for determining r-RNA gene numbers. Drosophila Information Service 58:170, 1982. e-Pub 1982.
Sehgal CB, Gandhi V. Breakdown of protein bodies in cotyledons of pigeon pea during germination. Indian J Exp Biol 19:341-344, 1981. e-Pub 1981.
Sehgal CB, Gandhi V. Cytochemical studies on the origin and development of protein bodies in the cotyledons of pigeon pea. J Cytol Genet 15:196-201, 1980. e-Pub 1980.
Sehgal CB, Parikh, V. A technique for making aniline blue black stained preparations permanent. J Cytol Genet 12:99-101, 1977. e-Pub 1977.

Invited Articles

Timofeeva, N, Jain, N, Gandhi, VV. Ibrutinib and venetoclax in combination for chronic lymphocytic leukemia: Synergy in practice. Blood Neoplasia 1(3), 2024. e-Pub 2024. PMID: 39949788.
Tantawy SI, Timofeeva N, Sarkar A, Gandhi V. Targeting MCL-1 protein to treat cancer: opportunities and challenges. Front Oncol 13:1226289, 2023. e-Pub 2023. PMID: 37601693.
Timofeeva N, Gandhi V. Ibrutinib combinations in CLL therapy: Scientific rationale and clinical results. Blood Cancer J 11(4):79, 2021. e-Pub 2021. PMID: 33927183.
Groenland SL, Ratain MJ, Chen LS, Gandhi V. The Right Dose: From Phase I to Clinical Practice. Am Soc Clin Oncol Educ Book 41:92-106, 2021. e-Pub 2021. PMID: 34010057.
Bose P, Gandhi V. Managing chronic lymphocytic leukemia in 2020: an update on recent clinical advances with a focus on BTK and BCL-2 inhibitors. Fac Rev 10:22, 2021. e-Pub 2021. PMID: 33718939.
Vangapandu HV, Jain N, Gandhi V. Duvelisib: a phosphoinositide-3 kinase δ/γ inhibitor for chronic lymphocytic leukemia. Expert Opin Investig Drugs 26(5):1-8, 2017. e-Pub 2017. PMID: 28388280.
Kadia TM, Gandhi V. Nelarabine in the Treatment of Pediatric and Adult Patients with T-Cell Acute Lymphoblastic Leukemia and Lymphoma. Expert Rev Hematol 10(1):1-8, 2017. e-Pub 2017. PMID: 27869523.
Gandhi V, Jalali R. A Conference of New Ideas in Cancer-Challenging Dogmas. Cancer Res 77(2):234-237, 2017. e-Pub 2017. PMID: 28062401.
Bose P, Gandhi V. Recent therapeutic advances in chronic lymphocytic leukemia. F1000Res 6:1924, 2017. e-Pub 2017. PMID: 29152232.
Patel P, Vora H, Aggarwal BB, Gandhi V, Mehta K, Pathak S. Prevention and Treatment of Cancer: Hypes and Hopes 6th International Translational Cancer Research Conference. Anticancer Res 36(9):4971-5, 2016. e-Pub 2016. PMID: 27630358.
Yang Q, Modi P, Newcomb T, Quéva C, Gandhi V. Idelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular Lymphoma. Clin Cancer Res 21(7):1537-42, 2015. e-Pub 2015. PMID: 25670221.
Mehta K, Gandhi V, Pathak S, Aggarwal BB, Grover RK. Multi-targeted Approach to Cancer Treatment: An International Translational Cancer Research Symposium. Anticancer Res 34(11):6791-5, 2014. e-Pub 2014. PMID: 25368293.
Zaman S, Wang R, Gandhi V. Targeting the Apoptosis Pathway in Hematologic Malignancies. Leuk Lymphoma 55(9):1980-92, 2014. e-Pub 2014. PMID: 24295132.
Gandhi V, Plunkett W, Cortes JE. Omacetaxine: a protein translation inhibitor for treatment of chronic myelogenous leukemia. Clin Cancer Res 20(7):1735-40, 2014. e-Pub 2014. PMID: 24501394.
Yang Q, Chen LS, Gandhi V. Mechanism-based combinations with Pim kinase inhibitors in cancer treatments. Curr Pharm Des 20(42):6670-81, 2014. e-Pub 2014. PMID: 25341939.
Balakrishnan K, Gandhi V. Bcl-2 antagonists: a proof of concept for CLL therapy. Invest New Drugs 31(5):1384-94, 2013. e-Pub 2013. PMID: 23907405.
Cervantes-Gomez F, Chen LS, Orlowski RZ, Gandhi V. Biological Effects of the Pim Kinase Inhibitor, SGI-1776, in Multiple Myeloma. Clin Lymphoma Myeloma Leuk 13(Suppl 2):S317-S329, 2013. e-Pub 2013. PMID: 23988451.
DiNardo CD, O'Brien S, Gandhi V, Ravandi F. Elacytarabine (CP-4055) in the treatment of acute myeloid leukemia. Future Oncol 9(8):1073-82, 2013. e-Pub 2013. PMID: 23902239.
Gandhi V, Mehta K, Pathak S, Aggarwal BB. Meeting Report: Leaders in Translational Cancer Research Meet in Udaipur, a Historical Town of India: An International Symposium on Translational Cancer Research: Cancer Prevention. Udaipur, Rajasthan, India, December 16-19, 2011. Anticancer Res 33(4):1777-81, 2013. e-Pub 2013. PMID: 23564834.
Yang Q, Chen LS, Neelapu S, Gandhi V. Combination of Pim Kinase Inhibitor SGI-1776 and Bendamustine in B-Cell Lymphoma. Clin Lymphoma Myeloma Leuk 13(Suppl 2):S355-S362, 2013. e-Pub 2013.
Balakrishnan K, Gandhi V. Protein Kinases: Emerging therapeutic targets in chronic lymphocytic leukemia. Expert Opin Investig Drugs 21(4):409-423, 2012. e-Pub 2012. PMID: 22409342.
Tam C, Gandhi V. Modifying the immune system to treat chronic lymphocytic leukemia. Leuk. Lymphoma 53(2):177-178, 2012. e-Pub 2012. PMID: 21895547.
Peng X, Gandhi V. ROS-activated anticancer prodrugs: A new strategy for tumor-specific damage. Therapeutic Delivery 3(7):823-833, 2012. e-Pub 2012. PMID: 22900465.
Balakrishnan K, Gandhi V. The micros in harmony: microRNA and microenvironment. Leuk Lymphoma 52(9):1626-9, 2011. e-Pub 2011. PMID: 21740342.
Chen LS, Balakrishnan K, Gandhi V. Inflammation and survival pathways: Chronic lymphocytic leukemia as a model system. Biochem Pharmacol 80(12):1936-1945, 2010. e-Pub 2010. PMID: 20696142.
Al-Kali A, Gandhi V, Ayoubi M, Keating M, Ravandi F. Forodesine: review of preclinical and clinical data. Future Oncol 6(8):1211-1217, 2010. e-Pub 2010. PMID: 20799866.
Gandhi V, Mehta K, Pathak S, Ravindran B, Mishra S, Aggarwal BB. City of temples discusses signaling templates in cancer cells. Third International Symposium on Translational Cancer Research: Cell Signaling & Cancer Therapy. Bhubaneswar, Orissa, India, December 18th through 21st, 2009. Anticancer Res 30(6):2477-80, 2010. e-Pub 2010. PMID: 20651411.
Ghanem H, Jabbour E, Faderl S, Gandhi V, Plunkett W, Kantarjian HM. Clofarabine in leukemia. Expert Rev Hematol 3(1):15-22, 2010. e-Pub 2010. PMID: 21082931.
Stellrecht CM, Gandhi V. Myeloma antioxidant status: The good, the bad and the reactive. Leuk Lymphoma 50(5):691-93, 2009. e-Pub 2009. PMID: 19347768.
Sampath D, Gandhi V. Dialing up a notch. Leuk Lympho 50:158-9, 2009. e-Pub 2009.
Stellrecht CM, Gandhi V. Met receptor tyrosine kinase as a therapeutic anticancer target. Cancer Lett 280(1):1-14, 2009. e-Pub 2009. PMID: 19100682.
Gandhi V. Forodesine. Hematology Meeting Reports 3(1):70, 2009. e-Pub 2009.
Sampath D, Gandhi V. Dialing resistance up a Notch. Leuk Lymphoma 50(2):158-159, 2009. e-Pub 2009. PMID: 17927518.
Faderl S, Gandhi V, Kantarjian HM. Potential role of novel nucleoside analogs in the treatment of acute myeloid leukemia. Curr Opin Hematol 15(2):101-107, 2008. e-Pub 2008. PMID: 18300755.
Kantarjian HM, Jeha S, Gandhi V, Wess M, Faderl S. Clofarabine: past, present, and future. Leuk Lymphoma 48(10):1922-1930, 2007. e-Pub 2007. PMID: 17852710.
Gandhi V, Balakrishnan K. Forodesine- A T-cell targeted therapeutic. Sem. Oncol 34 (Suppl.5)(6):8-13, 2007. e-Pub 2007. PMID: 18086347.
Gandhi V. p53 as a predictor for chemotherapy response in CLL cells. Leuk. Lympho 48(2):219-220, 2007. e-Pub 2007. PMID: 17325877.
Mehta K, Gandhi V, Aggarwal BB. All pathways to cancer apoptosis meeting in Thiruvananthapuram (India). Cell Death Differ 13:2163-4, 2006. e-Pub 2006. PMID: 16741526.
Gandhi V. Forodesine-Preclinical Studies. Hematologica Reports 2:35-37, 2006. e-Pub 2006.
Gandhi V, Keating MJ, Bate G, Kirkpatrick D. Nelarabine. Nature Reviews Drug Discovery 5:17-18, 2006. e-Pub 2006.
Ravandi F, Gandhi V. New purine nucleoside analogues for T-cell acute lymphoblastic leukemia T-ALL) and lymphoma. Expert Opinion on Investigational Drugs 15:1601-1613, 2006. e-Pub 2006.
Gandhi V, Plunkett W. Clofarabine and nelarabine: Two new purine nucleoside analogs. Curr. Opin. Oncol 18:584-590, 2006. e-Pub 2006.
Gandhi V. Guest Commentaries: Clofarabine: A viewpoint. Pediatric Drugs 7:5, 2005. e-Pub 2005.
Faderl S, Gandhi V, Keating MJ, Jeha S, Plunkett W, Kantarjian HM. The role of clofarabine in hematologic and solid malignancies-development of a next-generation nucleoside analog. Cancer 103:1985-1995, 2005. e-Pub 2005.
Cooper T, Kantarjian H, Plunkett W, Gandhi V. Clofarabine in adult acute leukemias: Clinical success and pharmacokinetics. Nucleosides, Nucleotides, and Nucleic Acids 23:339-345, 2004. e-Pub 2004.
Gandhi V. Metabolism and mechanisms of action of bendamustine: rationales for combination therapies. Semin Oncol 29(4 Suppl 13):4-11, 2002. e-Pub 2002. PMID: 12170425.
Gandhi V, Plunkett W. Cellular and clinical pharmacology of fludarabine. Clinical Pharmacokinet 41:93-103, 2002. e-Pub 2002. PMID: 11888330.
Rodriguez CO, Gandhi V. Nelarabine: A new drug for hematological malignancies. Haematologica 86(Suppl 1-11):43-47, 2001. e-Pub 2001.
Nabhan C, Krett N, Gandhi V. Gemcitabine in hematologic malignancies. Curr. Opinion Oncol 13:514-521, 2001. e-Pub 2001.
Gandhi V, Estey E, Keating MJ, Plunkett W. Fludarabine potentiates metabolism of arabinosylcytosine in patients with acute myelogenous leukemia during therapy: An Update. J. Clin. Oncol. Classic Papers & Current Comments 4:9-18, 1999. e-Pub 1999.
Aguayo A, Cortes JE, Kantarjian HM, Beran M, Gandhi V, Plunkett W, Kurtzberg J, Keating MJ. Complete hematologic and cytogenetic response to 2-amino-9-beta-D-arabinosyl-6-methoxy-9H-guanine in a patient with chronic myelogenous leukemia in T-cell blastic phase: a case report and review of the literature. Cancer 85:58-64, 1999. e-Pub 1999. PMID: 9921974.
Plunkett W, Kawai Y, Sandoval A, O'Brien S, Keating MJ, Gandhi V. Mechanism-based rationales for combination therapies of lymphoid malignancies. Hematologica 87(Suppl 10):73-77, 1999. e-Pub 1999.
Plunkett W, Huang P, Gandhi V. Gemcitabine: Actions and interactions. Nucleosides Nucleotides 167:1261-1270, 1997. e-Pub 1997.
Plunkett W, Huang P, Searcy CE, Gandhi V. Gemcitabine: Preclinical pharmacology and mechanisms of action. Sem. Oncol 23(Suppl 10):3-15, 1996. e-Pub 1996.
Gandhi V, Estey EH, Keating MJ, Plunkett W. Intracellular pharmacodynamics in leukemia therapy. Japanese J. Clin. Hematol 37:369-379, 1996. e-Pub 1996.
Plunkett W, Gandhi V. Pharmacology of purine nucleoside analogues. Hematology Cell Therapy 38:s67-s74, 1996. e-Pub 1996.
Keating MJ, O'Brien S, McLaughlin P, Dimopoulos M, Gandhi V, Plunkett W, Lerner S, Kantarjian H, Estey E. Clinical experience with fludarabine in hemato-oncology. Hematology Cell Therapy 38:s83-s91, 1996. e-Pub 1996.
Plunkett W, Huang P, Gandhi V. Preclinical characteristics of gemcitabine. Anti-Cancer Drugs 6(Suppl 6):7-13, 1995. e-Pub 1995.
Gandhi V, Mineishi S, Yang Y, Huang P, Chubb S, Chapman AJ, Nowak BJ, Hertel LW, Plunkett W. Difluorodeoxyguanosine: cytotoxicity, metabolism, and effects on DNA synthesis in human leukemia cells. Sem. Oncol 22(Suppl 11):61-67, 1995. e-Pub 1995.
Plunkett W, Huang P, Y-Z X, Heinemann V, Grunewald R, Gandhi V. Gemcitabine: Metabolism, mechanisms of action, and self-potentiation. Sem. Oncol 22(Suppl 11):3-10, 1995. e-Pub 1995.
Keating MJ, O'Brien S, Plunkett W, Robertson LE, Gandhi V, Estey E, Dimopoulos M, Cabanillas F, Kemena A, Kantarjian H. Fludarabine phosphate: A new active agent in hematologic malignancies. Semin Hematol 31(1):28-39, 1994. e-Pub 1994. PMID: 7510070.
Keating MJ, McLaughlin P, Plunkett W, Robertson LE, O'Brien S, Gandhi V, Gregoire V, Yang L, Cabanillas F. Fludarabine: Present status and future development in chronic lymphocytic leukemia and lymphoma. Annals Oncol 5(Suppl 2):s79-s83, 1994. e-Pub 1994.
Plunkett W, Gandhi V. Evolution of the arabinosides and the pharmacology of fludarabine. Drugs 47(Suppl 6):30-38, 1994. e-Pub 1994. PMID: 7525187.
Gandhi V, Huang P, Plunkett W. Fludarabine inhibits DNA replication: A rationale for its use in the treatment of acute leukemias. Leuk Lymphoma 14 Suppl 2:3-9, 1994. e-Pub 1994. PMID: 7881348.
Gandhi V, Estey E, Plunkett W. Modulation of arabinosylcytosine metabolism during leukemia therapy. Adv Exp Med Biol 370:119-124, 1994. e-Pub 1994. PMID: 7544948.
Keating MJ, O'Brien S, Robertson LE, Kantarjian H, Dimopoulos M, McLaughlin P, Cabanillas F, Gregoire V, Li YY, Gandhi V. The expanding role of fludarabine in hematologic malignancies. Leuk Lymphoma 14 Suppl 2:11-16, 1994. e-Pub 1994. PMID: 7533576.
Plunkett W, Gandhi V. Cellular pharmacodynamics as a guide to leukemia therapy. Cancer Bulletin 46:8-14, 1994. e-Pub 1994.
Plunkett W, Gandhi V, Huang P, Robertson LE, Yang LY, Gregoire V, Estey E, Keating MJ. Fludarabine: pharmacokinetics, mechanisms of action, and rationales for combination therapies. Semin Oncol 20(5 Suppl 7):2-12, 1993. e-Pub 1993. PMID: 8235690.
Gandhi V, Estey E, Keating MJ, Plunkett W. Biochemical modulation of arabinosylcytosine for therapy of leukemias. Leuk Lymphoma 10 Suppl:109-114, 1993. e-Pub 1993. PMID: 8481660.
Plunkett W, Gandhi V. Cellular pharmacodynamics of anticancer drugs. Semin Oncol 20(1):50-63, 1993. e-Pub 1993. PMID: 8475410.
Gandhi V. Fludarabine for treatment of adult acute myelogenous leukemia. Leuk Lymphoma 11(Suppl 2):7-13, 1993. e-Pub 1993. PMID: 8124234.
Keating MJ, O'Brien S, Robertson LE, Kantarjian H, Dimopoulos M, McLaughlin P, Cabanillas F, Gregoire V, Yang LY, Gandhi V. New initiatives with fludarabine monophosphate in hematologic malignancies. Semin Oncol 20(Suppl 7)(5 Suppl 7):13-20, 1993. e-Pub 1993. PMID: 7694371.
Plunkett W, Gandhi V. Pharmacokinetics of arabinosylcytosine. J. Infusional Chemother 20:50-63, 1992. e-Pub 1992.
Gandhi V, Huang P, Xu YZ, Heinemann V, Plunkett W. Metabolism and action of 2',2'-difluorodeoxycytidine: self-potentiation of cytotoxicity. Adv Exp Med Biol 309A:125-130, 1991. e-Pub 1991. PMID: 1789190.
Plunkett W, Huang P, Gandhi V. Metabolism and action of fludarabine phosphate. Semin Oncol 17(5 Suppl 8):3-17, 1990. e-Pub 1990. PMID: 1699280.
Plunkett W, Huang P, Gandhi V. Metabolism and action of fludarabine. Seminars Oncol 17(Suppl.5):3-17, 1990. e-Pub 1990.
Plunkett W, Gandhi V, Chubb S, Nowak B, Heinemann V, Mineishi S, Sen A, Hertel LW, Grindey GB. 2',2'-difluorodeoxycytidine metabolism and mechanism of action in human leukemia cells. Nucleosides Nucleotides 8:775-785, 1989. e-Pub 1989.
Venketeswaran S, Gandhi V, Romano EJ, Nagmani R. Mass propagation of selected trees for biomass by tissue culture. in NATO adv. Study Inst. Ser. Ser. A-Life Sci 67:191-204, 1983. e-Pub 1983.
Gandhi V, Parikh V. The central cell of angiosperms. Botanica 27:52-58, 1977. e-Pub 1977.
Gandhi V, Parikh V. Suspensor in angiosperms. Botanica 25:84-90, 1975. e-Pub 1975.

Professional Educational Materials

Gandhi V, Banerjee P. Faculty of 1000: Hematology, evaluation of Lionakis MS et al., Cancer Cell 2017, 31(6):833-843.e5]. In F1000Prime, 16 Sep 2017. https://f1000.com/prime/727663539#eval793535341, 2017.
Gandhi V, Yang Q. Faculty of 1000: Hematology, evaluation of Seeley-Fallen MK et al., Proc Natl Acad Sci U S A 2014, 111(27):9881-6. http://F1000Prime.com/718465476#eval793497211, 2014.
Gandhi V, Vangapandu H. Faculty of 1000: Hematology, evaluation of Ferreira PG et al., Genome Res 2014, 24(2):212-26. http://f1000.com/prime/718184644, 2014.
Gandhi V. Faculty of 1000: Hematology, evaluation of Cunningham JT et al., Cell 2014, 157(5):1088-103. http://F1000Prime.com/718415464#eval793498136, 2014.
Gandhi V, Balakrishnan K. Faculty of 1000: Hematology, evaluation of Lapalombella R et al., Blood 2012, 120(23):4621-34. http://F1000Prime.com/717972961#eval793469752, 2013.
Gandhi V, Shah P. Faculty of 1000: Hematology, evaluation of Talab F et al., Mol Cancer Res 2013, 11(5):541-54. http://F1000Prime.com/718007505#eval793476062, 2013.
Gandhi V, Yang Q. Faculty of 1000: Hematology, evaluation of Chen L et al., Cancer Cell 2013, 23(6):826-38. http://F1000Prime.com/718019534#eval793483059, 2013.
Gandhi V. Faculty of 1000: Hematology, evaluation of Wang ML et al., N Engl J Med 2013, 369(6):507-16. http://F1000Prime.com/718021375#eval793481853, 2013.
Gandhi V, Zaman S. Faculty of 1000: Hematology, evaluation of Katayama R et al., Cancer Res 2013, 73(10):3087-96. http://F1000Prime.com/718106555#eval793483727, 2013.
Gandhi V, Sarkar A. Faculty of 1000: Hematology, evaluation of Lovén J et al., Cell 2013, 153(2):320-34. http://F1000Prime.com/718008052#eval793483061, 2013.
Cervantes-Gomez F, Gandhi V. Faculty of 1000 Hematology: evaluation of Li L et al, Cancer Cell 2012 Feb 14 21 (2): 266-281. http://f1000.com/717952986, 2012.
Yang Q, Gandhi V. Faculty of 1000 Hematology: evaluation for Zhang L et al. Blood 2012 Sep 11; doi:10.1182/blood-2012-04-424630. /f1000.com/contributor/evaluate/article/717960029, 2012.
Gandhi V, Balakrishnan K. Faculty of 1000 Medicine: evaluation for Bronisz A et al, Nat Cell Biol 2012 Feb 14 2:159-167. http://f1000.com/14214959, 2012.
Zaman S, Gandhi V. Faculty of 1000: Hematology, evaluation of Kentsis A et al, Nature Medicine 2012 Jul; 18(7):1118-22. http://f1000.com/prime/717959975, 2012.
Gandhi V. Faculty of 1000 Medicine: evaluations for Chapman MA et al, Nature 2011 March 24 471: 467-472. http://f1000.com/9595957#eval13313056, 2011.
Gandhi V, Yang Q. Faculty of 1000: Hematology, evaluation of Watanabe A et al., Leukemia 2011, 25(8):1324-34. http://F1000Prime.com/11185957#eval12168055, 2011.
Gandhi V, Stellrecht C. Faculty of 1000: Hematology, evaluation of Hu R et al., Cancer Res 2011, 71(20):6524-34. htt://F1000Prime.com/13042956#eval14726305, 2011.
Gandhi V, Stellrecht C. Faculty of 1000 Medicine: evaluations for Joffre C et al, Nat Cell Biol 2011 Jul 13 (7) 827-837. http://f1000.com/14217956. Nat Cell Biol, 2011.
Gandhi V, Balakrishnan K. Faculty of 1000: Hematology, evaluation of Moussay E et al., Proc Natl Acad Sci U S A 2011, 108(16):6573-8. http://F1000Prime.com/11671956#eval12741054, 2011.
Gandhi V, Yang Q. Faculty of 1000 Medicine: evaluations for Quintana, AM et al, PLoS One, 2011, 6: e17362-17369. http://f1000.com/10669956#eval11552054, 2011.
Yang Q, Gandhi V. Faculty of 1000 Hematology: evaluation for Inuzuka H et al, Nature 2011 Mar 3 471 (7336) 104-109. http://f1000.com/11285956, 2011.
Gandhi V, Chen L. Faculty of 1000: Hematology, evaluation of Eiring AM et al., Cell 2010, 140(5):652-65. httP://F1000Prime.com/4112956#eval3892054, 2010.
Gandhi V, El-Mabhouh, A. Faculty of 1000 Medicine: evaluations for Ghosh AK et al, Blood 2010 March 4 115 (9): 1755-1764. http://f1000medicine.com/article/id/2809971/evaluation, 2010.
Gandhi V. Faculty of 1000 Medicine: evaluations for Schwickart M et al, Nature 2010 January 7 463 (7277): 103-107. http://www.f1000medicine.com/article/id/3265959/evaluation, 2010.
Gandhi V, Burger J. Faculty of 1000 Medicine: evaluations for Vogler M et al, Blood 2009 Apr 30 113 (18): 4403-4413. http://f1000medicine.com/article/id/1161112/evaluation, 2009.
Gandhi V. Combination of fludarabine and arabinosylguanine in CLL: Preclinical data and rationale for protocol design. CLL - The Cutting Edge, 1998.

Editorials

Aslan B, Tantawy SI, Gandhi V. Curing CLL. Blood Adv 7(9):1926-1928, 2023. PMID: 36355806.
Craciun I, Gandhi V. Publisher’s Note: Lymphatics, a New Open Access Journal. Lymphatics, 2022.
Timofeeva N, Gandhi V. Metabolism meets apoptosis in AML. Leuk Lymphoma 62(3):1-3, 2021. PMID: 33356786.
Stellrecht C, Zaman S, Gandhi V. The MET Receptor Tyrosine Kinase as a Therapeutic Target in Multiple Myeloma. Journal of Leukemia 2(2), 2014.
Balakrishnan K, Gandhi V. Uncoupling endoplasmic reticulum stress and autophagy: a potential implication for chronic lymphocytic leukemia therapy. Leuk Lymphoma 54(12):2581-3, 2013. PMID: 23656199.
Gandhi V. A new feature in Leukemia & Lymphoma: "Emerging drug profile". Leuk Lymphoma 54(10):2131-2, 2013. PMID: 24041378.
Gandhi V, Balakrishnan K. CCL2 in chronic lymphocytic leukemia: a macro in microenvironment?. Leuk Lymphoma 53(10):1849-1850, 2012. PMID: 22563818.
Gandhi, V. Yet another nucleoside analog for pancreatic cancer. Gastroenterology 140(2):400-404, 2011. PMID: 2172332.
Gandhi V. Targeting Kinases in CML CLL. Blood 116(12):1999-2000, 2010. PMID: 20864583.
Burger JA, Gandhi V. The lymphatic tissue microenvironments in chronic lymphocytic leukemia: In vitro models and the significance of CD40-CD154 interactions. Blood 114(12):2560-2561, 2009. PMID: 19762501.
Gandhi V, Balakrishnan K, Chen LS. Mcl-1: the 1 in CLL. Blood 112(9):3538-3540, 2008. PMID: 18948586.
Gandhi V. Questions about gemcitabine dose rate: answered or unanswered?. J Clin Oncol 25(36):5691-5694, 2007. PMID: 18089862.

Book Chapters

Jain N, Paul S, Pemmaraju N, Gandhi V. Chapter 69: Principles of Targeted Therapies for Hematologic Malignancies. In: Wintrobe’s Clinical Hematology. 15. Wolters Kluwer, 1454-1467, 2023.
Bertilaccio MTS, Zhang R, Banerjee P, Gandhi V. In Vitro Assay to Study CLL and Monocyte Interactions. In: Methods Mol Biol, 113-119, 2019.
Aslan B, Ayres ML, Gandhi V. Ex Vivo Pharmacological Profiling in Chronic Lymphocytic Leukemia Cells. In: Methods Mol Biol, 19-25, 2019.
Vangapandu HV, Gandhi V. Extracellular Flux Assays to Determine Oxidative Phosphorylation and Glycolysis in Chronic Lymphocytic Leukemia Cells. In: Methods Mol Biol, 121-128, 2019.
Parker WB, Gandhi V. Clofarabine: Structure, mechanism of action, and clinical pharmacology. In: Chemotherapy for Leukemia: Novel Drugs and Treatment. Springer, 261-286, 2016.
Vangapandu H, Gandhi V. Chronic lymphocytic leukemia at genomic level. In: Multi-Targeted Approach to Treatment of Cancer. Springer, 2015.
Patel V, Balakrishnan K, Gandhi V. Apoptosis pathways in chronic lymphocytic leukemia: Role of the microenvironment and therapeutic strategies. In: Multi-Targeted Approach to Treatment of Cancer. Springer, 2015.
Chen LS, Gandhi V. PIM Kinases in AML. In: Targeted Therapy of Acute Myeloid Leukemia. Springer, 2015.
Stellrecht CM, Gandhi V. CML: M.D. Anderson experience. In Chronic Myeloid Leukemia; An Update: Ed. Agarwal, MD. In: The Image Productions, 2007.
Gandhi V, Plunkett W. In Deoxynucleoside Analogs. In: Clofarabine: Mechanisms of action, pharmacology, and clinical investigations, 2006.
Vega BS, Gandhi V. In Drug Resistance in Malignant Disease. In: Mechanisms of Glucocorticoid Actions and Resistance in Multiple Myeloma, 2005.
Stellrecht CM, Krett N, Ayres M, Rosen S, Gandhi V. Acute Leukemias IX: Basic Research, Experimental Approaches and Novel Therapies. In: 8-chloro-cAMP serves as a prodrug for the RNA directed nucleoside analog, 8-chloro-adenosine, 193-199, 2003.
Faderl S, Gandhi V, Kantarjian H, Plunkett W. In Cancer Chemotherapy and Biological Response Modifiers Annual 20. In: New nucleoside analogs, 37-58, 2002.
Plunkett W, Gandhi V. In Cancer Chemotherapy and Biological Response Modifiers Annual 19. In: Purine and pyrimidine nucleoside analogs, 21- 45, 2001.
Gandhi V, Plunkett W. In The Chronic Lymphocytic Leukemias: Revised and Expanded. In: Combination strategies for purine nucleoside analogs, 195-208, 2001.
Keating M, Kantarjian H, Gandhi V, O’Brien S, Koller C, Kornblau S, Beran M, Andreeff M, Plunkett W, Freireich E. Acute Leukemias VII: Experimental Approaches and Novel Therapies. In: FLAG-Ida, an effective regimen for high risk AML, 828-833, 1998.
Plunkett W, Ruiz van Haperen VW, Huang P, Gandhi V. In Ovarian Cancer 5. In: Gemcitabine: A strategy for combination therapy in ovarian cancer, 185-394, 1998.
Gandhi V, Estey E, Seymour JF, Sampath D, Du M, Ayers M, Keating MJ, Plunkett W. In Acute Leukemias VII: Experimental Approaches and Novel Therapies. In: Modulation of ara-C metabolism to improve AML response, 577-583, 1998.
Plunkett W, Gandhi V, Rodriguez CO, Keating MJ. In Acute Leukemias VII: Experimental Approaches and Novel Therapies. In: Cellular metabolism and T-ALL specificity of arabinosylguanine: A review, 614-619, 1998.
Plunkett W, Gandhi V. In Nucleoside Analogs in Cancer Therapy. In: Nucleoside analogs: Cellular pharmacology, mechanisms of action, and strategies for combination therapy, 1-36, 1997.
Hertel LW, Kroin JS, Grossman CS, Grindey GB, Dorr AF, Storniolo AMV, Plunkett W, Gandhi V, Huang P. In Biomedical Frontiers of Fluorine Chemistry. In: Synthesis and biological activity of 2'.2'-difluorodeoxycytidine (gemcitabine), 265-278, 1996.
Gandhi V, Du M, Chapman AJ, Huang P, Estey E, Keating MJ, Plunkett W. In Acute Leukemias V: Experimental Approaches and Management of Refractory Diseases. In: Fludarabine and ara-C combination for treatment of adult acute myelogenous leukemia: Pharmacokinetic and pharmacodynamic effects, 25-31, 1996.
Gandhi V, Estey E, Plunkett W. In Purine and Pyrimidine Metabolism in Man VIII. In: Modulation of arabinosylcytosine metabolism during leukemia therapy, 119-124, 1995.
Gandhi V, Keating MJ, Estey E, Plunkett W. In Acute Leukemias: Prognostic Factors and Treatment Strategies III. In: Modulation of arabinosylcytosine metabolism by fludarabine: Therapy for acute myelogenous leukemia, 135-139, 1993.
Plunkett W, Gandhi V, Kantarjian H, Keating MJ. In Acute Leukemias: Pharmacokinetics and Management of Relapsed and Refractory Disease. In: Pharmacologically guided leukemia therapy, 253-257, 1992.
Gandhi V, Estey E, Keating MJ, Plunkett W. In Acute Leukemias III: Pharmacokinetics and Management of Relapsed and Refractory Disease. In: Biochemical basis for combination chemotherapy, 258-261, 1992.
Plunkett W, Gandhi V. In Chronic Lymphocytic Leukemia. In: Cellular metabolism of nucleoside analogues in CLL: Implication for drug development, 1997-220, 1992.
Gandhi V, Huang P, Xu YZ, Heinemann V, Plunkett W. In Purine and Pyrimidine Metabolism in Man VII, Part A. In: Metabolism and action of 2', 2'-difluorodeoxycytidine: Self-potentiation of cytotoxic activity, 125-130, 1991.
Plunkett W, Gandhi V, Grunewald R, Heinemann V, Estey E, Keating M. In Acute Myelogenous Leukemia: Progress and Controversies. In: Pharmacologically directed design of AML therapy, 481-492, 1990.
Venketeswaran S, Nagmani R, Gandhi V. In Bioenergy 84. In: Tissue culture propagation of selected tree genera for biomass, 47-51, 1985.
Parikh V, Sehgal CB. In Advances in Plant Reproductive Physiology. In: Structure and function of the endosperm in Cajanus cajan, 219-221, 1977.

Books (edited and written)

Gandhi V, Mehta, K, Grover, R, Pathak, S, Aggarwal, BB. Multitargeted Approach to Treatment of Cancer. Springer, 2015.

Letters to the Editor

Horiuchi D, Abdulkadir SA, Gandhi V, Goga A, Tutt A. RE: Lin et al. (2019) Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials. Science Translational Medicine, 2019.
Jain N, Gandhi V, Wierda W. Ibrutinib and Venetoclax for First-Line Treatment of CLL. Reply. N Engl J Med 381: 789, 2019.

Less

CV information above last modified March 10, 2026

Varsha Gandhi, Ph.D.

Present Title & Affiliation

Primary Appointment

Dual/Joint/Adjunct Appointment

Research Interests

Education & Training

Degree-Granting Education

Postgraduate Training

Experience & Service

Faculty Academic Appointments

Administrative Appointments/Responsibilities

Other Professional Positions

Extramural Institutional Committee Activities

Editorial Activities

Honors & Awards

Professional Memberships

Selected Presentations & Talks

Local Presentations

National Presentations

International Presentations

Grant & Contract Support

Selected Publications

Peer-Reviewed Articles

Invited Articles

Professional Educational Materials

Other Articles

Editorials

Book Chapters

Books (edited and written)

Letters to the Editor

Patient Reviews

Related Links

Care Centers and Clinics

Departments and Divisions

Labs

Help #EndCancer

Varsha Gandhi, Ph.D.

Present Title & Affiliation

Primary Appointment

Dual/Joint/Adjunct Appointment

Research Interests

Education & Training

Degree-Granting Education

Postgraduate Training

Experience & Service

Faculty Academic Appointments

Administrative Appointments/Responsibilities

Other Professional Positions

Extramural Institutional Committee Activities

Editorial Activities

Honors & Awards

Professional Memberships

Selected Presentations & Talks

Local Presentations

National Presentations

International Presentations

Grant & Contract Support

Selected Publications

Peer-Reviewed Articles

Invited Articles

Professional Educational Materials

Other Articles

Editorials

Book Chapters

Books (edited and written)

Letters to the Editor

Patient Reviews

Request an Appointment

Related Links

Care Centers and Clinics

Departments and Divisions

Labs

Clinical Trials

Help #EndCancer

Give Now

Donate Blood

Shop UT MD Anderson